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ABSTRACT
How insulin resistant muscle responds to mechanical overload (MOV) is not well understood.
Using immunohistochemical analysis and immunoblotting, we investigated whether Lean Zucker
(LZ) and insulin resistant Obese Zucker rats (OZ) respond in a similar fashion to MOV. Five
young adult (2 months old) male LZ and OZ rats were subjected to a surgical ablation of the
gastrocnemius muscle and overloaded for 8 weeks. MOV-induced increases in soleus muscle
mass and average fiber cross-sectional area were attenuated in OZ compared to LZ animals. This
reduction in OZ muscle adaptation was associated with decreased activity / phosphorylation
levels of STAT3, β-catenin and calcineurin. These data suggest that insulin resistance may
decrease the ability of skeletal muscle to hypertrophy and that this impairment may be due to
alterations in the ability of insulin-resistant muscle to activate STAT3, β-catenin and calcineurin
signaling.
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CHAPTER 1 
 
INTRODUCTION 
 
It is estimated that 246 million people worldwide have diabetes and it is likely that this 
will increase to 380 million by 2025 (International Diabetes Federation, 2006). Diabetes is a 
disease in which the body does not produce or properly use insulin. The cause of diabetes 
continues to be a mystery, although both genetic and environmental factors such as obesity and 
lack of exercise appear to play roles. There are 23.6 million children and adults in the United 
States, or 7.8% of the population, who have diabetes. In addition, there is an estimated 5.7 
million people who are unaware that they have the disease. The cost of treating diabetes has a 
tremendous impact on health care costs, and the disease process itself further initiates a higher 
risk for a variety of medical conditions including coronary artery disease, retinopathy, 
neuropathy, and nephropathy.  Indeed, the economic burden of diabetes in the United States is 
reflected by the annual $174 billion health care cost (Centers for Disease Control 2007).  
Exercise has long been recognized to have important health benefits for people with type 
2 diabetes. The molecular events underlying exercise-induced adaptations in diabetic muscle 
remain unraveled. It is thought that beneficial effects of exercise on structural and functional 
adaptations of muscle are mediated through the activation of various signaling molecules which 
activate intracellular cascades involved in regulating changes in gene expression, glucose uptake, 
glycogen synthesis and protein synthesis. Similar to that seen with aerobic exercise modalities 
(30, 48, 133) , recent data has suggested that anaerobic exercise may also be beneficial in the 
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treatment of diabetes (18, 45, 62, 65, 66, 72, 127, 135). Mechanical overload in the form of 
synergist ablation (14, 21) provides a chronic stimulus that initiates skeletal muscle adaptation by 
increasing the workload of selected muscles by ablation of a few or all synergistic muscles (84). 
How insulin resistance or diabetes affects the response to mechanical overload is not well 
understood. Furthermore, it is not known if the adaptive potential of insulin resistant muscle 
differs from that of non-diabetic controls. A greater understanding of how insulin resistant 
muscle responds to hypertrophic stimuli may help to unravel new treatment modalities for use in 
the diabetic population.  
 
PURPOSE 
 
The purpose of the present investigation is to determine whether type 2 diabetes affects 
the response of skeletal muscle to an overload stimulus. The working hypothesis for this study 
was that diabetes would negatively impact the ability of skeletal muscle to exhibit hypertrophy.  
 
SPECIFIC AIMS 
 
We hypothesize that diabetes will attenuate the ability of skeletal muscle to undergo 
muscle growth in response to a strong hypertrophic stimulus. To test this hypothesis two specific 
aims are proposed:  
 
Specific Aim #1: To determine if the muscle wet weight, muscle fiber cross sectional area, 
myosin heavy chain expression and activation/phosphorylation of STAT-3, β-catenin, 
calcineurin and Gsk3-β proteins are altered in the diabetic soleus muscle.  
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Hypothesis: Type 2 diabetes will be associated with alterations in the muscle wet weight, 
muscle fiber cross sectional area, myosin heavy chain expression and 
activation/phosphorylation of STAT-3, β-catenin, calcineurin and Gsk3-β proteins.  
 
Specific Aim # 2: To determine if diabetes affects the ability of mechanical overload to 
induce increases in muscle wet weight, muscle fiber cross sectional area, changes in myosin 
heavy chain expression and the activation/phosphorylation of STAT-3, β-catenin, Calcineurin 
and Gsk3-β proteins in the soleus muscle. 
 
Hypothesis: Type 2 diabetes will be associated with alterations in the ability of mechanical 
overload to induce changes in muscle wet weight, muscle fiber cross sectional area , myosin 
heavy chain (MHC) expression and activation/phosphorylation of STAT-3, β-catenin, 
Calcineurin and Gsk3-β proteins in the soleus muscle.    
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
INTRODUCTION 
 
   A review of the pertinent literature concerning the present study will be presented 
in the following chapter. The following areas will be addressed: 1.) Different methods for 
inducing skeletal muscle hypertrophy and effects of hypertrophy on skeletal muscle,  2.) 
Molecular mechanisms and key components in skeletal muscle hypertrophy, and 3.) The obese 
syndrome X Zucker rat strain as an animal model for type 2 diabetes investigation. 
 
Methods for inducing hypertrophy in animal model 
 
This section will summarize a variety of methods for inducing skeletal muscle 
hypertrophy focusing on animal models. These paradigms include compensatory hypertrophy, 
stretch hypertrophy, alteration of hormonal levels, dietary supplementation, electrical stimulation 
and resistance exercise. 
 
Compensatory hypertrophy 
The compensatory hypertrophy model was involves the severing of a tendon or complete 
removal of a synergistic muscle. This results in compensation of target muscle with respect to 
maintenance of total tension initially produced by entire muscle group. In this model, increasing 
functional demand results in muscle hypertrophy (124). Two models have been used to induce 
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compensatory hypertrophy; tenotomy and ablation of synergistic muscle groups. While both of 
these models induce hypertrophy, they are the result of a continuous stretch and load on the 
muscle without normal periods of recovery.  
            Tenotomy induces hypertrophy by severing the tendon of a synergistic muscle (93, 118). 
Generally, this model results in rapid increase of target muscle mass after 4 to 7 days of surgery 
and reaches a plateau within 2 to3 weeks (124). The rapid peak increase in muscle mass after 4 
to 7 days of tenotomy appears to be caused by stretch rather than an increased functional load on 
the target muscle functional group after tenotomy, because the tension produced by the 
antagonistic muscle group becomes greater  relative to the group with the incapacitated 
muscle(124). Also, this early enlargement may be due to muscle edema rather than increased 
muscle fiber size (14). One of the major problems of this model is that tendon reattachment can 
occur after some period of time. Another aspect is difficult to infer this adaptation from this 
model to normal hypertrophy achieved through resistance training is the lack of a recovery 
period from mechanical overload. 
Synergistic ablation involves removal of the synergistic muscle completely, avoiding 
possible tendon reattachment. The hypertrophic response to ablation is somewhat different from 
that of tenotomy. The hypertrophy of target muscle is much greater and rate of increase is 
consistent rather than transient  (1, 46). Snow and colleagues found that fiber cross sectional area 
of target muscle was decreased 3 days following ablation surgery (113). However, after initial 
inflammatory response, target muscle cross sectional area increased up to 40% after 8 weeks of 
post-surgery. The initial inflammatory response was hypothesized to be the result of surgical 
trauma including edema and leukocyte infiltration (11). Target muscle absolute peak twitch 
tension and maximal tetanic tension were increased by ablation (76). However, peak tetanic 
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tension expressed per cross sectional area was slightly depressed (3 to 8%) indicating in an 
abnormal hypertrophic response rather than strength training where specific tension remains 
constant. The main advantages of synergist ablation model for compensatory hypertrophy are 
that one can utilize the contra lateral non-surgical limb as the control, a large and rapid 
hypertrophic response, and free from complications of tendon reattachment as in tenotomy 
method (6). On the other hand, the disadvantages include post surgical complications like 
inflammation and edema, and the lack of similarity of mimicking progressive resistance training 
as it lacks recovery period from mechanical overload (6). 
  An enormous amount of data is available with surgical ablation model for 
understanding the various adaptations of skeletal muscle with hypertrophy (19, 20, 25, 81, 106, 
121). Nonetheless, very little is known about response of diabetic muscle for hypertrophic 
stimuli. However, a study by Armstrong and colleagues investigated the effects of synergist 
ablation on skeletal muscle hypertrophy in chronic streptozotocin induced diabetic rats (13). This 
study revealed that significant difference in muscle enlargement as reflected by muscle wet 
weight between the plantaris in normal rat compared to the diabetic rat. Another interesting 
finding revealed a 41% increase in diameter in the slow oxidative fibers of the diabetic rat 
whereas the fast glycolytic fibers experienced the smallest increase in diameter during muscle 
hypertrophy. These findings indicate differences in adaptation of diabetic muscle to hypertrophic 
stimuli compared to normal muscle. The underlying mechanisms to explain these differences 
between normal and diabetic muscle are still not known.  
 
Stretch hypertrophy 
The stretch-induced hypertrophy model involves imposing a chronic stretch on a 
particular muscle group. Many studies used this passive stretch to induce muscle hypertrophy in 
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last three decades (7, 15, 86, 140). The responsiveness of this model is much greater than that in 
compensatory model resulting in 126% to 318% in increase muscle mass (10, 64). Evidence of 
hyperplasia remains controversial in this model. Several investigators have reported an increase 
number of muscle fibers (7, 10) while others have not (57, 64). Overall, chronic stretch model 
seems to induce hyperplasia at the early stage but intermittent stretch model can induce 
hyperplasia only following long period of time at least 28 days (9). Total muscle protein is 
increased in enlarged muscle by an increasing of protein synthesis without change of protein 
degradation (22).  
 
Alteration of hormonal level in body 
Hormonal treatments have been used to increase skeletal muscle mass and strength. 
These include growth hormone and insulin-like growth factor-I. Growth hormone (GH) has 
positive effects on skeletal muscle growth, possibly via endocrine insulin like growth factor-I 
stimulated protein accretion (55). The administration of GH to hypophysectomized animal 
increased muscle mass, total protein, RNA content, ribosome content and enzymes related 
to protein synthesis compared to non-GH treatment group (50). The combination of 
supplemental GH and exercise in old rats resulted in a substantial increase of muscle mass and 
maximal tension compared with muscle from old rats receiving supplemental GH alone (8). The 
insulin-like growth factor-I (IGF-1) is thought to be one of the most important factors for 
induction of skeletal muscle hypertrophy among the various factors including growth hormone, 
insulin, creatine and other substances. IGF-1 binds to a receptor predominantly located in the 
plasma membrane resulting in a signaling cascade within the cell that affects various cytoplasmic 
substrates. Traditionally, IGF-1 is believed to play a major role in somatic growth and 
development mediated by growth hormone in liver (51). However, IGF-1 is also produced by 
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most tissues of the body and is abundant in the circulation. IGF-1 may also be expressed locally 
at the muscle level through autocrine/paracrine synthesis (2). 
 
Dietary supplementation 
Creatine plays a role as creatine phosphate in regenerating adenosine triphosphate in 
skeletal muscle to help maintain muscle contraction (49). Over the last few years, the effects of 
creatine supplementation on exercise performance have been intensively studied. The consistent 
findings from the studies are that exercise performance involving short periods of powerful 
activity can be enhanced by creatine supplementation, especially during repeated bouts of 
exercise (29, 73, 122). However, the effects of creatine supplementation on isometric strength, 
maximal force, aerobic performance and fatigue resistance are not clear. Several other 
supplements such as Clenbuterol, beta-hydroxy-betamethlbutyrate (HMB), branched-chain 
amino acids (BCAA) have been utilized for inducing skeletal muscle hypertrophy (96). 
 
Electrical stimulation 
Electrical stimulation is another method used to induce adaptations in skeletal muscle.  
In electrical stimulation, an isolated target muscle can be stimulated. This allows for muscle of 
the contralateral limb (unstimulated) to be used as an internal control. Also, electrical stimulation 
activates all motor units equally, which contrasts the normal recruitment pattern. Furthermore, 
electrical stimulation has been shown to induce significant amount of physiological changes in 
relative short period of time. Wong and Booth (1990) stimulated the plantar flexor muscle group 
using a Teflon-coated platinum electrode wire inserted into both side of lower leg muscle. The 
muscle was stimulated to contract against a weighted resistance. They demonstrated 18% 
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increase in gastrocnemius muscle mass after 16 weeks training (136). These results are 
comparable to the increase 14 - 18% in muscle mass observed following 6 - 8 weeks of 
concentric and eccentric resistance training using electrical stimulation (33). 
 
Resistance Training 
Several animal models resembling human resistance exercise have been used to study 
the effect of resistance training on skeletal muscle mass and function. One of the most consistent 
findings from resistance training is increased muscle mass and strength. Chronic eccentric 
contraction of rat soleus has been accomplished by flexing the ankle via electrical stimulation 
(78). For example, using a modification of Booth’s original model Wong and colleagues (136) 
trained rat soleus eccentrically as a countermeasure for non weight bearing muscle atrophy. They 
demonstrated the potential of eccentric exercise training as an effective countermeasure to non-
weight bearing atrophy. Another model used for weight training in animals is the ladder climbing 
exercise. Animals have been trained to climb vertically with weight attached to their tail (5, 107, 
134, 141). Such studies have demonstrated a 5 - 26% increase in relative muscle mass. Results of 
these studies vary because of differences in training protocol, species and muscles studied. 
  
Effects of hypertrophy on skeletal muscle   
 
Myosin heavy chain (MHC) isoform composition is a common marker of skeletal muscle 
physiology. MHC is a major component of the skeletal muscle contractile protein, myosin. 
Mature rat skeletal muscle expresses four different MHC isoforms, types I, IIa, IIx and IIb. In 
general, MHC isoforms range from slow, oxidative (MHC type I) to fast, glycolytic (MHC type 
IIx and IIb) types. Due to higher concentrations of glycolytic enzymes and higher rates of 
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ATPase activity, muscles containing a predominance of fast MHC isoforms generally reach 
fatigue before muscles containing predominantly slow MHC isoforms. Therefore, the 
distribution of MHC isoform types (i.e., slow vs. fast isoforms) and the metabolic parameters 
associated with each type are directly related to muscle fatigability.  
Skeletal muscle is referred to as a “plastic” tissue, meaning that proteins that regulate 
contraction and metabolism can alter isoform type protein content depending on the pattern of 
stimuli the muscle receives. For example, increased neuromuscular activation due to tonic, low 
frequency stimulation (101) or functional overload (42) induces slow fiber-like protein 
phenotypes. In contrast, reduced neuromuscular activity due to spinal cord transection (120) or 
reduced body weight bearing through hind limb suspension (24) increases the percentages of fast 
fiber-like protein phenotypes. The change of muscle phenotype is evident at molecular level, 
with transition of contractile protein isoforms as well as alteration of glycolytic and oxidative 
enzymes. MHC isoforms are widely used to measure the direction and extent of fiber type 
switching, with type I MHC representing the slowest form and type IIb as the fastest one. During 
transition, the general direction is I  →IIa → IIx → IIb , with the extent of transition depending 
on the intensity and duration of the stimuli. 
Altered expression patterns of MHC fiber phenotypes are linked to multifactorial 
mechanisms. Genetic factors intrinsic to muscle, neurotrophic factors, mechanical factors, 
metabolic factors and hormonal factors have been implicated in altering MHC isoform 
composition (44). For example, levels of circulating hormones potentially regulate MHC isoform 
protein expression. Reductions to circulating growth hormone in hypophysectomized rats 
decrease MHC type I and MHC type IIa mRNA levels and increase MHC type IIb mRNA levels 
(83).  Also, thyroid hormone status affects MHC isoform expression. Hypothyroidism is 
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consistently associated with fast-to slow MHC isoform transitions (100). Conversely, 
hyperthyroidism increases the percentage of fast MHC fiber types (33). 
Molecular mechanisms and key components in muscle hypertrophy 
 
A growing body of evidence suggests that the serine/threonine protein phosphatase, 
calcineurin, has been linked to molecular pathways that regulate skeletal muscle mass and fiber-
type specific protein expression  (42, 91, 94, 111, 119). Although some studies have failed to 
implicate calcineurin as a key regulator in these processes (43, 117), a potential role for 
calcineurin-dependent in the regulation of skeletal muscle mass and fiber-type specific protein 
expression in functional overload rat muscle is intriguing. 
Calcineurin is a Ca2+/calmodulin-dependent protein phosphatase that  dephosphorylates 
nuclear factor of activated T cells (NFATc1), which exposes the nuclear localization sequence 
and allows for NFATc1 nuclear translocation. Nuclear NFATc1 binds to conserved DNA 
sequences that activate the transcription of several growth regulatory genes and fiber type-
specific genes (36, 94, 138). Furthermore, calcineurin has also been suggested to play an 
important role in myonuclear accretion, a necessity for skeletal muscle growth (88). In mature 
skeletal muscle, calcineurin is tethered to the Z-disc structures of sarcomeres through its 
association with a novel structural protein called calsarcin (53, 82).Because calcineurin is 
localized to Z-disc structures, it is in close proximity to the Ca2+-release channel (RyR). This 
microenvironment may provide a potential link between calcineurin activation and regulated 
Ca2+ release. Moreover, this localization of calcineurin to SR luminal Ca2+ reserves potentially 
couples muscle contractile activity to transcriptional activation of fiber type-specific and growth-
dependent genes. Calcineurin expression may also be higher in fast fibers since they may require 
higher levels of calcineurin to maintain an appropriate level of sensitivity of gene expression to 
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Ca2+ fluctuations. Because Ca2+ transients are less frequent in fast than in slow muscle fibers 
(61), fast fibers may require higher levels of calcineurin to increase the probability of Ca2+-
calmodulin activation of calcineurin. Conversely, slow fibers may require less calcineurin, 
because they are activated more frequently and encounter more frequent Ca2+-release events 
(35, 61).  
 Many recent studies examining Akt signaling in skeletal muscle provide compelling 
evidence that the PI3K/Akt/mTOR pathway signaling is very important during hypertrophy. 
Phospatidylinosital-3-kinase (PI3K) exists ubiquitously in various tissues but it known to play a 
key role in skeletal muscle proliferation/differentiation, protein synthesis, and muscle cell 
survival (56). Levels of PI3K increased in hypertrophied skeletal muscle and decrease with 
atrophy (28, 105). PI3K acts through a variety of membrane-phospholipids including 
phospatidylinosital-4,5-biphosphate (PtdIns-4,5-P2), phospatidylinosital-3,4,5-triphosphate 
(PtdIns-3,4,5-P3) and phospatidylinosital-3,4-biphosphate (PtdIns-3,4-P2) (137). PtdIns-3, 4, 5-
P3 acts as a binding site for two protein kinases associated with PI3K:  Akt and phospoinositide- 
dependent protein kinase (PDK1). These two downstream kinases subsequently initiate a 
signaling cascade of kinase intermediates involved in protein synthesis, gene transcription, 
glucose metabolism and cell proliferation (56).  
Akt, which exists primarily as the isoform Akt1 in skeletal muscle is a serine/threonine 
kinase that is activated by both PI3K-dependent and-independent mechanisms (109). Akt 
normally resides in cytosol and translocates to the cell membrane and is activated 
(phosphorylated) by PDK1 at two specific amino acid residues on the kinases (Thr308 and 
Ser473) (3). Phosphorylation of both sites is required for full activation of the kinase. Akt has 
been shown to have critical roles in hypertrophy and the prevention of muscle atrophy in vivo 
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(28) and it is activated by muscle contraction in a rapid and transient fashion (109). Over-
expression of a constitutively active form of Akt in rodent skeletal muscle via transfection (95) 
or genetic manipulation (80) has been shown to promote a 2-fold increase in muscle fiber 
diameter in both healthy and atrophied muscle (28). Ten to fourteen days of muscle unloading 
via hindlimb suspension in rat results in a decrease in Akt content and activity and muscle 
atrophy (28, 115). Downstream of this kinase, Akt phosphorylates and activates the mammalian 
target of rapamycin (mTOR) that is critical to the regulation of proliferation and skeletal muscle 
growth (27). The mTOR, a serene/threonine kinase, has also been shown to be activated 
following functional overload (28) and treatment with insulin,. IGF-1 (98) and essential amino 
acids (104). Although mTOR signaling appears to be complex, it is thought to primarily regulate 
protein translation through two distinct mechanisms: 1) phosphorylation of the ribosomal protein 
S6 kinase (p70S6K) AND 2) phosphorylation of the eukaryotic initiation factor binding protein, 
elF 4E-BP1. Together, p70S6K and 4E-BP1 coordinate the translation of proteins, the behavior 
of eukaryotic initiation factors and ribosomes (112). 
 The p70S6K is thought to play a critical role in regulating the translation of a class of 
mRNA transcripts, which contain an oligopyrimidine tract at their transcriptional start site (109) 
and therefore is an important signaling intermediate that leads to the activation of protein 
synthesis and muscle hypertrophy. Activated p70s6k hyperphosphorylates the ribosomal protein, 
S6, and enables the up-regulation of 5' TOP mRNA for encoding translational machinery and 
ribosomal proteins (4). Treatment of cells with rapamycin ( a blocker of mTOR) eliminates the 
phosphorylation (71) and activation of p70s6k and almost completely inhibits muscle 
hypertrophy (28). Activation of p70s6k is increased following in situ contraction (16), high 
frequency stimulation(92), and resistance exercise in vivo (48). This activation is often found to 
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be delayed and transient but remains elevated in hypertrophied skeletal muscle 36 hours 
following electrical stimulation (48). The degree of p70s6k phosphorylation is correlated with 
increase in muscle weight (16). Using humans, Koopman et al., (2006) reported that resistance 
exercise is associated with more pronounced phosphorylation of p70S6k in type II vs. type I 
muscle fibers (79). Similarly, in rats, the phosphorylation of upstream regulators of p70S6k likes 
PKB (or Akt) and mTOR was more pronounced in muscle tissue containing a greater proportion 
of type II muscle fibers (97, 108). Taken together, these findings suggest that intensity and time-
dependent regulation of p70S6k, and further that p70S6k stimulation in muscle may be fiber type 
specific. To our knowledge how diabetes affects the regulation of p70S6k to hypertrophic stimuli 
has not been examined. 
 
The obese syndrome X Zucker rat strain as an animal model for type 2 diabetes 
investigation. 
 
Overview of Diabetes Mellitus 
In general, diabetes mellitus is a disease where the body does not utilize insulin properly 
or does not produce insulin. Insulin is a polypeptide hormone, secreted by the pancreas that 
allows glucose to enter cells from the blood. A deficiency in this hormone, or the inability of 
cells to respond to it, causes abnormally high blood glucose levels, which can lead to numerous 
complications. Although there are some subtypes of diabetes now recognized, the two major 
types of diabetes are type 1 and type 2. Type 1 diabetes is an autoimmune disorder in which the 
body’s immune system destroys the beta cells of the pancreas (23). Therefore insulin is not 
produced. Type 1 diabetes is typically diagnosed in children and was previously referred to as 
juvenile onset diabetes or insulin dependent diabetes mellitus. Type 1 account for about 5-10% 
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of all cases of diabetes (23). The major type of diabetes, is type 2 diabetes. In type 2 diabetes, 
cells become insulin resistant then the pancreas can gradually lose the ability to produce insulin 
as the disease progresses. Several genetic and environmental factors lead to the development of 
the disease in most patients  (102). Type 2 diabetes is by far the most prevalent accounting for 
90-95% of all diagnosed cases (142).  To our knowledge research examining the signaling events 
thought to underlie hypertrophy-induced muscle plasticity in type 2 diabetes has not been 
performed.  
 
The obese syndrome X Zucker rat strain as an animal model 
 Animal models of Type 2 diabetes are likely to be as complex and heterogeneous as the 
human condition. Models where glucose intolerance is part of a wider phenotype of obesity, 
dyslipidaemia and hypertension may provide valuable insights into human Type 2 diabetes. 
The Goto Kakizaki (GK) rat which was developed by selective breeding of Wistar rat is an 
example of a type 2 diabetic model. The GK rat develops relatively stable hyperglycemia, has 
insulin resistance and impaired insulin secretion. The GK rat, in common with other animal 
models of diabetes, develops some features that can be compared with the complications of 
diabetes seen in humans. These include renal lesions, structural changes in peripheral nerves and 
abnormalities of the retina. It is also born with a reduced number of islets (102). This model is 
relatively slim and as such, does not mimic obesity related insulin resistance.  
 The KK mouse was selectively bred for large body size. Several different lines have been 
bred and they vary genetically and phenotypically (102). The KK mouse becomes obese as an 
adult, developing insulin resistance, islet cell hyperplasia, and mild hyperglycemia (102). 
Conversely, the Nagoya-Shibata-Yasuda (NSY) mouse spontaneously develops diabetes in an 
age-dependent manner and is not obese. This model is useful when studying age-related 
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phenotypes (102). The Psammomys obesus (the Israeli sand rat) is a vegetarian in its natural 
habitat, but when fed laboratory rat chow, it becomes obese, insulin resistant and hyperglycemic 
(102). The Zucker (fa/fa) rat is a model of monogenic obesity and diabetes along with the Ob/Ob 
mouse and db/db mouse. The db/db mouse and the fa/fa Zucker rat both have mutations in the 
hypothalamic receptor for leptin (102). 
Animal models of diabetes have provided, and continue to provide, extremely valuable 
insight to the disease. The genetically obese Zucker (fa/fa) rat was selected for the present 
investigation. This model is widely used in obesity related diabetes studies. The obese Zucker is 
developed through selective breeding and exhibits hyperinsulinemia, hyperlipidemia and 
hyperglycemia along with central adiposity. These characteristics are valuable for studying type 
2 diabetes in the context of metabolic syndrome, and should provide useful insight to the disease 
since many type 2 diabetics possess these same conditions. Insulin resistance in obese Zucker rat 
is mainly associated with impaired   insulin-stimulated GLUT-4 protein translocation (47, 77) 
and glucose transport activity(39, 63) and not the amount of carrier turnover stimulated by 
insulin (47, 54, 70). 
Previous studies indicate differences in the skeletal muscle tissue between obese Zucker 
rats and their lean counterparts in response to exercise. Ardevol and others exercised female lean 
and obese Zucker rats in a short, intense treadmill protocol. Oxygen consumption, carbon 
dioxide release, lactate and bicarbonate levels in venous and arterial blood were measured. It was 
concluded that fatigue appears earlier in obese rats due to loss of buffering ability caused by 
massive extra-muscular glycolysis (possibly in adipose tissue) and lactate production triggered 
by exercise-induced adrenergic stimulation (12). The same group studied differential substrate 
utilization by exercising and fatigued muscle in lean and obese Zucker rats. It was found that 
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lean rats managed their glycosyl units more efficiently than obese rats (12). Taken together, these 
data imply that metabolic differences exist between lean and obese Zucker rat muscle tissue in 
response to exercise. The obese Zucker fa/fa rat model has been used in early investigations 
demonstrating potential benefits of exercise training. Exercise training improves the skeletal 
muscle insulin resistance of the obese Zucker rat (31, 37, 58, 69). Hevener et al.,2000 
demonstrated exercise and thiazolidinedione therapy in the Zucker fatty (ZF) rat improved the 
glucose disposal rate (combined therapy, 52.4 +/- 2.9 mg x kg(-1) x min(-1), vs. untreated ZF, 
25.8 +/- 0.8 mg x kg(-1) x min(-1); P = 0.0001), total GLUT4 protein (twofold increase; P = 
0.001), insulin receptor substrate (IRS)-1 protein (fourfold increase; P = 0.0001), and Akt 
phosphorylation (2.9-fold increase; P = 0.002). Whether the adaptation of skeletal muscle to 
synergistic ablation differs in the Obese Zucker rat compared to age-matched control animals has 
not be investigated. 
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CHAPTER 3 
 
 
 
 
Impaired overload-induced hypertrophy in Obese Zucker rat slow-twitch 
skeletal muscle  
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ABSTRACT 
 
The molecular signaling pathway linked to hypertrophy of the soleus muscle after mechanical 
overload in lean and obese Zucker rats has not yet been identified. Using Immunohistochemical 
analysis and Western blot, we investigated whether the lean Zucker (LZ) and obese Zucker rats 
(OZ) are responding in the same way to mechanical overloading. In the present study we 
hypothesized that, in the obese Zucker rat the capacity of skeletal muscle to undergo similar 
adaptations when subjected to an overload stimulus would be attenuated in comparison to 
muscles in lean zucker rats. Therefore, the purpose of the present study was to investigate the 
effect of mechanical overload (MOV) on muscle wet-weight (WW), muscle fiber cross-sectional 
area, myosin heavy chain expression and signaling molecules expression levels in the OZ rat. 
Five young adult (2 months old) male LZ and OZ rats were subjected to a surgical ablation of the 
gastrocnemius muscle and overloaded for 8 weeks. Mechanical overloading resulted in a 
significant increase in the wet weight 57.4% and 36%, (p<0.05) the average fiber cross-sectional 
area of slow fibers 29.7% and 3.9%, (p<0.05) and the MHC composition is indicated a increase 
in slow MHC isoforms 9.3% and 4.2%, (p<0.05) with concomitant loss of faster MHC isoforms 
44% and 34%, (p<0.05) of the soleus muscle in LZ and OZ rats respectively. Western blot 
analysis revealed that phosphorylation levels of STAT3 increased 21.5% and 8%, (p<0.05)        
β-catenin phosphorylation levels increased 47.5% and 18.1%, (p<0.05) and the levels of 
calcineurin increased 36.4% and 10.3%, (p<0.05) in lean and obese soleus muscle with overload 
respectively. These data suggests that impaired overload induced hypertrophy in OZ rats may be 
associated with decreased phosphorylation levels of STAT-3 and β-catenin and decreased 
activity of calcineurin compared with LZ rats. 
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INTRODUCTION  
 
           Type 2 (non-insulin dependent) diabetes mellitus (DM) is an emerging epidemic in 
Western cultures that is thought to afflict 246 million people worldwide (40). A number of 
studies employing strength training regimens have been shown to improve glycemic control, 
increase skeletal muscle size and strength, and positively change body composition suggesting 
that anaerobic exercise may be an effective strategy for the treatment of insulin resistance and 
type 2 diabetes (32, 34, 126, 131). Whether type 2 diabetes alters the ability of skeletal muscle to 
respond to an overload stimulus is not known.  
Various mechanical overload models have been developed to induce skeletal muscle 
growth and adaptations in animal models. Mechanical overload in the form of synergist ablation 
(14, 21) provides a chronic stimulus that initiates skeletal muscle adaptations by increasing the 
workload of selected muscles by ablation of a few or all synergistic muscles (84). The magnitude 
of muscle enlargement with synergist ablation as reflected by increases in muscle cross-sectional 
area, myofibrillar protein content, and muscle wet-weight is large and occurs rapidly; therefore, 
providing an opportunity to investigate the phenomena of skeletal muscle hypertrophy and 
adaptation (84).  
 The purpose of this study was to investigate the effect of mechanical overload on muscle 
wet-weight, muscle fiber cross-sectional area, myosin heavy chain expression and protein 
synthesis signaling pathways in normal and diabetic muscle. We hypothesized that type 2 
diabetes would be associated with differences in how overloading regulates muscle hypertrophy. 
To test this hypothesis overload induced alterations in muscle wet-weight, muscle fiber cross-
sectional area, myosin heavy chain expression and indices of protein synthesis were assessed in 
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skeletal muscle from normal and diabetic rats after 8 weeks of overloading. Taken together, our 
data suggest that diabetes affects how skeletal muscle adapts to muscle overload.  
 
MATERIALS AND METHODS 
 
Materials  
  
Anti- STAT-3  (#9132), β-catenin  (#9562), calcineurin (α-subunit) (#1956), phosphorylated 
STAT-3 (Ser 727) (#9134), phosphorylated β-catenin (#9561), Anti- p70S6k  (#9202), Akt  
(#9272), phosphorylated Ser421/Thr424 p70S6K (#9204), ±phosphorylated Thr308 Akt (#9275) and 
phosphorylated Ser473 ( #9271) Akt  Mouse IgG, and Rabbit IgG antibodies were purchased from 
Cell Signaling Technology (Beverly, MA).  Enhanced chemiluminiscence (ECL) western 
blotting detection reagent was from Amersham Biosciences (Piscataway, NJ).  Restore western 
blot stripping buffer was obtained from Pierce (Rockford, IL) and 3T3 cell lysates were from 
Santa Cruz Biotechnology (Santa Cruz, CA).  All other chemicals were purchased from Sigma 
(St. Louis, MO) or Fisher Scientific (Hanover, IL).  
 
Animal Care:  
 
All procedures were performed as outlined in the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
Animal Use Review Board of Marshall University. Young (4 week, n=5) male lean Zucker and 
young (4 week, n=5) male obese Zucker rats were obtained from the Charles River Laboratories. 
Rats were housed two to a cage in an AAALAC approved vivarium. Housing conditions 
consisted of a 12H: 12H dark-light cycle and temperature was maintained at 22° ± 2°C. Animals 
were provided food and water ad libitum and allowed to recover from shipment for at least two 
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weeks before experimentation. During this time the animals were carefully observed and 
weighed weekly to ensure none exhibited signs of failure to thrive, such as precipitous weight 
loss, disinterest in the environment, or unexpected gait alterations. 
 
Surgical procedures:  
 
Rats were anesthetized with a ketamine-xylazine cocktail in 1:4 ratio (50 mg/kg IP) and 
supplemented as necessary for reflexive response (32). In a sterile aseptic environment, the dorsal 
surface of the hindlimb was shaved and cleaned, and the superficial musculature was exposed by 
means of a proximal-to-distal incision through the skin and blunt separation of the skin and 
fasciae. The medial gastrocnemius and the proximal two-thirds of the lateral head of the 
gastrocnemius were carefully isolated by blunt manipulation of the tissues and were removed 
bilaterally. Care was taken to leave the nerve and vasculature supply to the remaining 
musculature undisturbed. Incomplete removal of the synergists was done to ensure that the nerve 
and vascular supply remained intact. Control animals did not undergo sham procedures, because 
previous research has demonstrated that sham operations had no effect on muscle mass in control 
animals (25). After recovery from anesthesia, animals were returned to their cages and were 
maintained in barrier housing for 8 wk.  
 
 
Determination of muscle fiber cross sectional area:   
 
Muscle fiber cross sections were projected at an objective magnification of ×20 to a 
computer equipped with software (Alpha ease software) to measure fiber CSA. The captured 
image of a fiber was traced on a computer monitor by using a handheld mouse. The software 
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package was calibrated to determine the area in micrometers squared. Fiber CSA was determined 
for type I fiber types. Average fiber CSA was determined for each muscle from the mean of all 
fibers traced for that muscle. To reduce experimental bias in the selection of fibers for 
measurement, all of the fibers on randomly selected screens were quantified. All area 
measurements were performed with the researcher blinded to the treatment of each respective 
section. Tracing of fibers was practiced until a coefficient of variation of <5% was repeatedly 
achieved. Whole muscle cross-sectional area (MCA) (Fig 3) was estimated by utilizing the 
following algorithm: CSA (mm2) = (muscle mass (mg) x cos angle of pinnation)/fiber length 
(Lf) (mm) x muscle density (mg/mm3) (75). The angle of pinnation was ignored as it is an 
insignificant correction because the pinnation angle is not pronounced. This approach is 
consistent with our past practice with muscles of simple architecture and small angle of pinnation 
for both the OZ and LZ, respectively (75). The Lf was estimated by the following: Lf (mm) = 
muscle length (Lm) x (Lf/Lm). The Lm was measured at Lo, and Lf/Lm was assumed to be 0.42 
according to (75). Muscle density was assumed to be 1.06 mg/mm3 according to (75). 
 
Preparation of protein isolates and immunoblotting:  
  
Muscles were pulverized in liquid nitrogen using a mortar and pestle until a fine powder 
was obtained. After washing with ice cold PBS, pellets were lysed on ice for 15 minutes in T-
PER (2mL/1g tissue weight) (Pierce, Rockford, IL) and centrifuged for 5 minutes at 14000 X g 
to pellet particulate matter. This process was repeated twice and the supernants combined for 
protein concentration determination using the Bradford method (Pierce, Rockford, IL). Samples 
were diluted to a concentration of 2.0 μg/μl in SDS loading buffer, boiled for 5 minutes, and 40 
μg of protein were separated using 10% SDS-PAGE gels. Transfer of protein onto nitrocellulose 
  24  
 
 
membranes, verification of transfer and determination of equal loading between lanes and 
membranes was determined as outlined previously. Protein immuno-detection was performed as 
outlined by the antibody manufacturer while immunoreactive bands were visualized with ECL 
(Amersham Biosciences). Exposure time was adjusted at all times to keep the integrated optical 
densities (IODs) within a linear and non-saturated range, and band signal intensity was 
quantified by densitometry using a flatbed scanner (Epson Perfection 3200 PHOTO) and 
Imaging software (Alpha Ease FC). Molecular weight markers (Cell Signaling) were used as 
molecular mass standards and NIH 3T3 cell lysates were included as positive controls. To allow 
direct comparisons to be made between the concentration levels of different signaling molecules, 
immunoblots were stripped and re-probed with Restore western blot stripping buffer as detailed 
by the manufacturer (Pierce, Rockford, IL).  
 
Myosin heavy chain preparation:   
 
A 20 mg proximal section from both the OZ and LZ OV and contralateral control soleus 
muscle was utilized for the separation of myosin heavy chains (MHCs) with the incorporation of 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis following the methods of (26, 103). 
The samples were diluted 1:10 (3 l per sample) on gels that were stained with silver staining 
(Reiser et al.,1997) to determine MHC isoform composition expressed as the percentage of the 
total MHC isoform pool (103). The separating gel was comprised of a 7% Acrylamide (50:1), 
30% Glycerol, 3.0 M 4X separating buffer (pH 8.8), 1M glycine, 10% SDS, 10% ammonium 
persulfate, and N’, N’, N’ N’-tetramethylethylenediamine (TEMED) and the stacking gel was 
comprised of 4% acrylamide (50:1), 5% Glycerol, 0.5 M stacking buffer (pH 6.8), 0.1M EDTA, 
10% SDS, 10% ammonium persulfate, and TEMED (103). The gels initially were run in a 
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Hoefer Scientific SE 600 unit (Hoefer Scientific Instruments, San Francicso, CA) at a constant 
voltage of 75 volts (V) and a temperature of 8C for 2 hours. Thereafter, the gels ran in the Hoefer 
Scientific SE 600 unit (Hoefer Scientific Instruments, San Francicso, CA) for 24 hours at a 
constant voltage of 300 V and a temperature of 8C. Each gel was analyzed by utilizing a 
scanning densitometer (Model GS 300, Hoefer Scientific Instruments, San Francicso) for the 
purpose of quantifying the relative amounts of MHC isoforms in each sample. The linearity of 
desitometric scanning of MHC isoforms has been tested and determined by Reiser et al.1997.  
 
Statistics:  
 
Results are presented as mean ± SEM. Data were analyzed by using the Sigma Stat 3.0 
statistical program. Data was analyzed using a two-way ANOVA followed by the Student-
Newman-Keuls post-hoc testing when appropriate. P <0.05 was considered to be statistically 
significant.  
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RESULTS  
 
Insulin resistance alters overload-induced increases in muscle mass and fiber cross 
sectional area.  
 
The average body mass of obese Zucker rats was ~54 % greater than lean counterparts 
(650.8 ± 21.6 g vs. 414 ± 15.1g; P< 0.05). Compared to lean animals, soleus muscle mass was 
~12% less (163 ± 8.4 mg vs. 186 ± 8.2 mg) in the obese Zucker rats. Muscle overload increased 
the mass of the soleus by 57.4% and 36% in lean and obese animals, respectively (P< 0.05) 
(Table 1). Similarly, the fiber CSA of Type I muscle fibers was increased by 29.7 (3539.7 ± 83.4 
and 4663.9 ± 251.0) and 3.9% (4317.8± 275.6 and 4506.9 ± 100.6) and whole muscle cross 
sectional area was increased by 42.6 (16.3 ± 0.8 and 23 ± 1.4) and 27.9% (14.51 ± 0.7 and 18.59 
± 1.5) in lean and obese rats, respectively (P< 0.05) (Table 2). 
With overload the Type I MHC was increased from 80.84 ± 4.2 to 89.2 ± 1.6 (9.3%) in 
lean rats and 88.7 ± 1.3 to 92.2 ± 3.8 (4.2 %) in obese animals. Type IIA MHC decreased from 
19.2 ± 4.2 to 10.8 ± 1.6% (43.5%) in lean rats and 11.3 ± 1.3 to 7.4 ± 3.8 (34.3%) in obese 
animals,  respectively (P< 0.05) (Table 3).  
 
Overload-induced muscle signaling is altered with insulin resistance.  
 
 The muscle content of STAT 3, β catenin and calcineurin in the obese Zucker soleus was 
21.5 ± 6.6% , 47.5 ± 5.7% and 36.4 ± 8.9 lower, respectively than that observed in their lean 
counterparts (P< 0.05) (Figs. 7, 8 and 9). Phosphorylation of STAT-3 in soleus muscles was 
determined after 8 weeks of overload and compared to control muscles. In the lean rat soleus, the 
phosphorylation of STAT-3 was increased by 21.5 ± 6.6% with overloading (Fig.7). Conversely, 
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in the obese rat soleus, the phosphorylation of STAT-3 was increased by only 8 ± 3.5 with 
overloading. Levels of phosphorylated β-catenin protein increased 47.5% (P < 0.05) in leans and 
18.1% in obese rats after 8 weeks of mechanical overload (Fig. 8). Levels of calcineurin protein 
increased by 36.4% in lean rats and increased by 10.3% in obese rats with mechanical overload 
(Fig. 9).  
Levels of phosphorylated Akt (Thr 308) and Akt (Ser 473) were increased 28.5 and7.5% 
(P < 0.05) in lean animals and decreased 2.3% and 22.3% in obese animals after 8 weeks of 
mechanical overload (Fig. 10, 11). Levels of phosphorylated Gsk3β protein increased 27.4%     
(P < 0.05) in leans and decreased 27.3% in obese rats after 8 weeks of mechanical overload (Fig. 
12). Levels of phosphorylated p70s6k protein increased 11.5% (P < 0.05) in lean animals and 
decreased 17.3% in obese rats after 8 weeks of mechanical overload (Fig. 13).  
 
 
  28  
 
 
 
DISCUSSION 
   
           The obese Zucker rat is insulin resistant and has been used as model of type 2 diabetes 
(39). It is thought that these animals closely simulate the disease evolution from insulin 
resistance to progressive beta cell failure/frank hyperglycemia that is seen in human type 2 
diabetes (114). Here we examine whether the soleus muscles from diabetic and nondiabetic 
animals undergo a similar adaptation to 8 weeks of synergistic ablation. Our findings suggest 
that diabetes is associated with alterations in how skeletal muscle responds to an overload 
stimulus.  
 
Diabetes alters overload-induced adaptations of the soleus muscle to synergistic ablation.  
 
Similar to previous reports, 8 weeks of muscle overload resulted in significant increases 
in muscle mass, muscle cross sectional area and mean fiber CSA (Figs 2, 3, 4) (67, 125). In 
addition, we also observed that synergistic ablation resulted in a significant change in myosin 
heavy chain expression (Fig. 5) with overload resulting in a shift towards a slow motor unit 
phenotype (68). Compared to lean animals, these responses appeared to be attenuated in the 
diabetic muscle. Taken together, these data suggest that the response of diabetic muscle to 
skeletal muscle overload is different to that observed in normal muscle. To investigate the 
potential mechanism(s) behind this difference in muscle adaptation we examined the regulation 
of several different signaling pathways that are thought to be involved mediating changes in 
muscle gene expression. It is thought that skeletal muscle remodeling in response to mechanical 
overload shares common features with many of the signaling events regulating the regenerative 
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processes following muscle injury (123, 132). STAT-3 signaling has been identified as a possible 
mediator of skeletal muscle regeneration (74) , but the importance of this pathway in the adaptive 
response of diabetic skeletal muscle to mechanical overload is not well understood. Compared to 
control animals, we found that the overload-induced activation (phosphorylation) of STAT-3 was 
diminished in diabetic muscle (Fig. 7). The β-catenin protein has recently been shown to be both 
necessary and sufficient for the hypertrophy of terminally differentiated cardiomyocytes (59). In 
cardiac muscle, active  β-catenin was found to be associated with Akt-mediated Gsk3-β  (Ser9) 
phosphorylation(59). Similar to what we observed for STAT-3, the activation (phosphorylation) 
of β-catenin was diminished in diabetic muscle (Fig. 8). 
Recently, calcineurin, a cytoplasmic calcium-regulated phosphatase has been implicated 
in the pathogenesis of hypertrophic cardiomyopathy (89, 116), and has emerged as a possible 
candidate in the signaling of skeletal muscle cellular growth and the fiber type transformation 
(36). Compared to control muscle, overload-induced changes in calcineurin levels were 
attenuated in the diabetic soleus. This finding corresponds nicely with the absence of change we 
found in myosin heavy chain expression with overload in the diabetic animals. Whether these 
changes are directly related or only correlated in nature will require further experimentation.  
 
Diabetes alters the activation of protein synthesis pathways in the overloaded soleus 
muscle. 
  
 Compared to lean animals, the mechanical overload induced phosphorylation of 
p70S6k (Thr 421 / ser 424) was significantly different in obese animals (Fig. 13). The p70S6k is 
a serine/threonine protein kinase and has been shown to play an important role in regulating 
protein synthesis. It is thought that p70S6k modulates protein synthesis, at least in part, by 
controlling the translation of numerous messenger RNA transcripts that encode components of 
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the translational apparatus (99).  Illustrating this fact is the finding that blockade of p70S6k 
activity results in a significant inhibition of protein synthesis in multiple cell systems (38, 41, 71, 
90, 139). In skeletal muscle, the contraction induced phosphorylation of p70S6K has been found 
to be elevated following HFES (17, 97, 98) and is highly correlated with increase in muscle mass 
following a resistance training program (17). To our knowledge, the influence of diabetes on 
p70S6k phosphorylation in response to muscle loading has not been reported before. The 
physiological significance of these alterations in p70S6k activation in diabetic muscle remains 
unclear; however it is interesting to note that previous reports have suggested that the insulin-
stimulated phosphorylation of p70S6k may be altered in diabetic rats (52, 60, 85). In the light of 
these studies, our data suggest that diabetes may affect how multiple stimuli may regulate the 
phosphorylation of p70S6k. In addition, our data suggest that the diminished hypertrophic 
response of diabetic muscle to overload may be related to alterations in p70S6k activation. 
Future studies employing a combination of approaches to stimulate p70S6k phosphorylation will 
certainly be of value in determining how diabetes may affect the regulation of p70S6k in skeletal 
muscle. Given the strong correlation between the phosphorylation level of p70S6k and degree of 
muscle hypertrophy seen by others, these data could suggest that diabetic muscle may be 
incapable of growth following a resistance based exercise program. This is not in agreement with 
the findings of Farrell and colleagues (48) who demonstrated that diabetic muscle is fully 
capable of undergoing muscle hypertrophy following 8 weeks of resistance training. The reasons 
for this apparent discrepancy are not entirely clear, but may lie in the difference in models and 
time points between the studies and a more comprehensive examination is needed. Irrespective 
of the mechanism, it is likely that diabetes-associated differences in the ability of skeletal muscle 
to induce p70S6K signaling could be of clinical importance given the potential role that this 
  31  
 
 
signaling pathway may play in regulating protein synthesis and the adaptation of skeletal muscle 
to increased mechanical overload.  
Akt is a serine/threonine kinase that has been shown to mediate certain types of muscle 
hypertrophy (28). Under non-stimulated conditions Akt is located in the cytoplasm and is 
thought to translocate to the plasma membrane upon activation, where it is phosphorylated by 
phosphinositide-dependent kinases (PDK) on its two principal regulatory sites Thr308 and Ser 
473 (130). Phosphorylation of both sites is essential for the activation of Akt. Similar to p70S6k, 
mechanical overload significantly increased the amount of Akt (Ser 473) and Akt (Thr 308) 
phosphorylation in non-diabetic muscle (Fig 10, 11). Similar findings regarding the effects of 
contractile activity on Akt phosphorylation in non-diabetic muscle have been reported previously 
(92, 110, 128). Similar to our findings with p70S6k, we observed that diabetic muscle exhibited 
an inability to activate Akt signaling following increased mechanical overloading (Fig. 10, 11). 
Since Akt resides upstream of p70S6k, it is likely that this decrease in Akt activation may be 
related to the diminished ability of diabetic muscle to activate p70S6k. Although this possibility 
is promising it should be noted that the functional role of Akt in regulating p70S6k signaling 
cannot be accurately assessed in the absence of further study to evaluate experimental 
manipulation of this protein. Additional studies perhaps employing strategies designed to directly 
inhibit or activate Akt signaling during mechanical overload may prove to be useful in 
addressing these possibilities.  
Why diabetic muscle may differ in its ability to activate Akt is not known. It has been 
postulated that the degree of Akt activation following contractile activity may be dependent upon 
the type of contractile activity, contraction intensity, and / or the duration of stimulation (98). 
Given this contention, it is plausible that differences in the signaling response between models 
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could be related to the time points chosen for evaluation. Future studies employing other time 
points would yield different findings. Alternatively, it is possible that the two groups experienced 
different amount of tension during the overload protocol. Although this possibility exists, we 
consider it unlikely that differences in contractile intensity, if present, are solely responsible for 
the alterations in muscle signaling we observe since each animal group was subjected to the 
same protocol of muscle loading. Similarly, it is also possible that a reduced availability of 
circulating growth factors, decreased expression of local growth factors or alterations in cytokine 
levels may also play a role regulating Akt signaling (87, 129). This latter possibility is an 
intriguing alternative that we are actively pursuing. 
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CHAPTER 4 
 
CONCLUSIONS 
 
1. Mechanical overload increased the soleus muscle wet weight in diabetic and non diabetic rats 
compared to corresponding controls but less in diabetic rats compared to non diabetic rats.  
2. Mechanical overload increased Type I average fiber and whole muscle CSA in non diabetic 
and diabetic rats compared to corresponding controls but less in diabetic rats compared to non 
diabetic rats. No statistical differences in type II average fiber CSA were observed.  
3. Mechanical overload increased type I MHC isoform with decrease in the type II MHC isoform 
in the non diabetic and diabetic soleus compared to the contralateral control soleus. However, 
the difference was not statistical and may be related to the large standard of error (i.e., large 
variation) observed within the type I MHC isoform among MOV diabetic rats. No statistical 
differences were observed between the diabetic and non diabetic rats MHC isoforms with 
muscle overload; however, the non diabetic rat presented with a statistical significant increase 
in expression of the type I MHC isoform in the contralteral soleus.  
4. Muscle overload significantly altered the expression of Stat3, β Catenin, Gsk3β, p70s6k, 
calcineurin and Akt in both diabetic and non diabetic rats. 
5. Mechanical overload significantly increased the phosphorylation levels of STAT3, β Catenin 
and Gsk3β in both non diabetic and diabetic rats but less in diabetic rats compared to non 
diabetic rats. 
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6. Mechanical overload significantly increases the phosphorylation levels of p70s6k, Akt 308 
and Akt 473 in non diabetic rats but no statistical significant difference in diabetic rats. 
              These data suggests that Type 2 diabetes is associated with alterations in the adaptation 
of slow twitch skeletal muscle to synergistic ablation.  
 
FUTURE DIRECTIONS 
 
The results of present study have shown that mechanical overload induced regulation of 
Stat3, β Catenin, Gsk3β, calcineurin and Akt/mTOR/p70S6k signaling may be altered in the 
skeletal muscles of the obese Zucker (fa/fa) rat model. Future experiments designed to 
experience these responses in other models of diabetes and other muscles (e.g. Plantaris, EDL) 
on muscle loading may give better understanding of altered regulation of these proteins with 
diabetes.  
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APPENDIX A 
Tables and Figures 
 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Effect of diabetes and functional overload on Soleus mass. Values are means ± SE for 
5 Lean and Obese rats. OV, functional overload; * Significant effect of OV, P < 0.05. † 
Significantly different from Lean, P < 0.05 
 
 Lean Zucker Obese Zucker 
Initial Body mass (g) 286.6 ± 28.2 429.2 ± 18.6 
Final Body mass (g) 414 ± 15.1* 650.8 ± 21.6* 
Soleus mass (mg) 186 ± 8.2 163 ± 8.4  
Soleus mass after overload (OV)(mg) 292 ± 15.8* 216 ± 12.8*† 
% change with overload(OV) 57.4* 36.0*† 
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Table 2 
 
 
 
 
 
 
 
 
Table 2: Effect of diabetes and functional overload on average Type I muscle fiber Cross 
Sectional Area (CSA) and Muscle Cross sectional Area (WMCSA).Values are means ± SE for 
5 Lean and Obese rats. OV, functional overload; CSA, cross-sectional area; * Significant effect 
of OV, P < 0.05. † Significantly different from Lean, P < 0.05    
 
Treatment  Fiber CSA(µm²) 
Muscle 
CSA(mm²)(MCA) 
Lean 3539.7 ± 83.4 16.3 ± 0.8 
Lean-OV  4663.9 ± 251.0* 23.0 ± 1.4* 
Obese 4317.8± 275.6 14.51 ± 0.7 
Obese-OV  4506.9 ± 100.6* 18.59 ± 1.5*† 
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Table 3 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Effect of diabetes and functional overload on muscle fiber Myosin heavy chain 
(MHC).Values are means ± SE for 5 Lean and Obese rats. OV, functional overload; MHC, 
Myosin heavy chain; * Significant effect of OV, P < 0.05.   
 
 
 
 
 
 
 
 
 
 
     MHC 
Treatment Type I Type II 
Lean 80.84 ± 4.2 19.2 ± 4.2 
Lean-OV  89.2 ± 1.6 10.8 ± 1.6* 
Obese 88.7 ± 1.3 11.34 ± 1.3 
Obese-OV  92.6 ± 3.8 7.4 ± 3.8* 
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Figure 1 
 
 
                                
Figure 1: Soleus wet weight of Lean Zucker (LZ) and Obese Zucker (OZ) rats at the beginning 
and end of the study. Values are means SE; n = 5 LZ and n = 5 OZ rats. * Significant effect of 
OV, P < 0.05. † Significantly different from Lean, P < 0.05 
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Figure 2 
 
 
 
 
                                         
 
 
Figure 2: Muscle Cross Sectional Area (MCA) of Lean Zucker (LZ) and Obese Zucker (OZ) rats 
at the beginning and end of the study. Values are means SE; n = 5 LZ and n = 5 OZ rats. * 
Significant effect of OV, P < 0.05. † Significantly different from Lean, P < 0.05 
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Figure 3 
 
      
                 
Figure 3: Representative myosin ATPase staining of soleus muscle samples (pH 9.4).  
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Figure 4 
 
 
                                 
Figure 4: Type I Fiber Cross Sectional Area of Lean Zucker (LZ) and Obese Zucker (OZ) rats at 
the beginning and end of the study. Values are means SE; n = 5 LZ and n = 5 OZ rats. * 
Significant effect of OV, P < 0.05. † Significantly different from Lean, P < 0.05 
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Figure 5 
 
 
 
                              
Figure 5: Myosin heavy chain isoforms. n = 4 OV and n = 5 CON Obese Zucker (OZ) Soleus 
muscles and n = 5 OV and n = 5 CON Lean Zucker soleus muscles 
 
 
 
 
 
                           
 
 
 
 
 
 
 
  43  
 
 
 
 
 
 
 
 
Figure 6 
 
 
 
                               
Figure 6: Myosin Heavy Chain of Lean Zucker (LZ) and Obese Zucker (OZ) rats at the 
beginning and end of the study. Values are means SE; n = 5 LZ and n = 5 OZ rats.  *Significant 
effect of OV, P < 0.05. † Significantly different from Lean, P < 0.05 
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Figure 7 
 
 
 
 
                             
 
                      
 
Figure 7:  Overload-induced pSTAT 3 (Ser 727) phosphorylation is altered with type 2 diabetes; 
*Significant effect of OV, P < 0.05. † Significantly different from Lean, P < 0.05 
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Figure 8 
 
 
 
                            
                      
 
Figure 8:  Overload-induced p-β-catenin phosphorylation is altered with type 2 diabetes;  
*Significant effect of OV, P < 0.05.  † Significantly different from Lean, P < 0.05 
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Figure 9 
 
 
           
                          
                 
 
Figure 9:  Overload-induced calcineurin activity is altered with type 2 diabetes; 
   * Significant effect of OV, P < 0.05.† Significantly different from Lean, P < 0.05 
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Figure 10 
 
 
                             
 
 
Figure 10:  Overload-induced p Akt473 phosphorylation is altered with type 2 diabetes;  
*Significant effect of OV, P < 0.05.  †Significantly different from Lean, P < 0.05 
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Figure 11 
 
 
                            
 
Figure 11:  Overload-induced p Akt 308 phosphorylation is altered with type 2 diabetes; 
*Significant effect of OV, P < 0.05.  †Significantly different from Lean, P < 0.05 
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Figure 12 
 
                        
                            
 
Figure 12:  Overload-induced pGsk3β phosphorylation is altered with type 2 diabetes;  
*Significant effect of OV, P < 0.05.  †Significantly different from Lean, P < 0.05 
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Figure 13 
 
 
 
                           
 
   Figure 13:  Overload-induced p-p70s6k (Ser 421/422) phosphorylation is altered with type 2 
diabetes; * Significant effect of OV, P < 0.05.†  Significantly different from Lean, P < 0.05 
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APPENDIX B 
Film properties, Raw data and Statistics 
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Soleus 
 
Film Properties Report for phospho-STAT3 
 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                      Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg             Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                        Transfer Voltage:  24V  Duration:  45 min 
Primary Antibody:  p-Stat 3                          Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit               Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  8 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl      
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl 
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-STAT 3 in Soleus muscle 
Raw IOD values (relative percentage) 
 
LZ C   LZ OV OZ C   OZ OV 
11.5 15.4 11.0 12.6 
14.0 15.7 9.2 9.6 
16.0 21.5 7.5 9.8 
12.8 19.8 3.9 7.8 
13.1 13.4 13.0 12.0 
11.6 12.5 11.8 11.6 
12.8 13.7 11.1 10.7 
11.3 13.2 13.3 13.0 
N 16 16 16 16 
Mean 12.9 15.7 10.1 10.9 
Standard Deviation 1.56 3.30 3.16 1.75 
Standard Error of the mean 0.40 0.85 0.81 0.45 
 
LZ C   LZ OV OZ C   OZ OV 
Relative Expression Level 1.00 1.22 0.78 0.85 
Standard error of the mean 0.03 0.07 0.06 0.04 
 
LZ C   LZ OV OZ C   OZ OV 
% RE 100.00 121.54 78.31 84.55 
SE 3.13 6.62 6.32 3.51 
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Statistics 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 1:14:05 PM      
       
Data source: Data 1 in Notebook 1       
       
Balanced Design       
       
Dependent Variable: p Stat3        
       
Normality Test: Passed (P = 0.756)     
       
Equal Variance Test: Passed (P = 0.393)     
       
Source of Variation  DF   SS   MS    F    P   
Model 1 114.398 114.398 17.338 <0.001  
Exp 1 25.639 25.639 3.886 0.059  
Model x Exp 1 7.783 7.783 1.18 0.287  
Residual 28 184.742 6.598    
Total 31 332.562 10.728    
       
       
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure.  
     
       
The difference in the mean values among the different levels of Exp is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Model.  There is not a statistically significant difference (P = 0.059).   
    
       
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.287)     
  
       
Power of performed test with alpha = 0.0500:  for Model : 0.984       
Power of performed test with alpha = 0.0500:  for Exp : 0.360       
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.0659     
  
       
Least square means for Model :        
Group Mean      
LZ 14.276      
OZ 10.494      
Std Err of LS Mean = 0.642       
       
Least square means for Exp :        
Group Mean      
C 11.49      
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OL 13.28      
Std Err of LS Mean = 0.642       
       
Least square means for Model x Exp :        
Group Mean      
LZ x C 12.887      
LZ x OL 15.664      
OZ x C 10.092      
OZ x OL 10.896      
Std Err of LS Mean = 0.908  
       
       
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
   
       
Comparisons for factor: Model       
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 3.781 2 5.889 <0.001 Yes  
       
       
Comparisons for factor: Exp       
Comparison Diff of Means p q P P<0.050  
OL vs. C 1.79 2 2.788 0.059 No  
       
       
Comparisons for factor: Exp within LZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 2.777 2 3.057 0.039 Yes  
       
       
Comparisons for factor: Exp within OZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 0.804 2 0.885 0.537 No  
       
       
Comparisons for factor: Model within C       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 2.795 2 3.078 0.038 Yes  
       
       
Comparisons for factor: Model within OL       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 4.768 2 5.25 0.001 Yes 
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Soleus 
Film Properties Report for phospho-βCatenin 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                            Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg           Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                 Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  p- β Catenin              Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit   Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl  
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-βCatenin in Soleus muscle 
Raw IOD values (relative percentage) 
 
LZ C   LZ OV  OZ C   OZ OV 
%C 12.7 21.7 10.2 11.6 
%C 11.3 15.3 8.0 9.1 
%C 12.3 20.4 10.0 11.6 
%C 13.1 15.4 8.4 8.6 
%C 12.8 16.5 9.7 11.6 
%C 11.7 15.0 10.4 10.5 
%C 9.6 15.7 12.5 14.7 
%C 8.8 16.1 7.5 12.9 
N 16 16 16 16 
Mean 11.5 17.0 9.6 11.3 
Standard Deviation 1.57 2.56 1.61 1.98 
Standard Error of the mean 0.41 0.66 0.42 0.51 
 
LZ C   LZ OV OZ C   OZ OV 
Relative Expression Level 1.00 1.47 0.83 0.98 
Standard error of the mean 0.04 0.06 0.04 0.04 
 
LZ C   LZ OV  OZ C   OZ OV 
% RE 100.00 147.49 83.09 98.14 
SE 3.52 5.74 3.60 4.43 
 
  58  
 
 
Statistics 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 1:22:56 PM      
       
Data source: Data 1 in Notebook 1       
       
Balanced Design       
       
Dependent Variable: p-beta catenin        
       
Normality Test: Passed (P = 0.638)     
       
Equal Variance Test: Passed (P = 0.899)     
       
Source of Variation  DF   SS   MS    F    P   
Model 1 116.879 116.879 30.075 <0.001  
Exp 1 104.125 104.125 26.794 <0.001  
Model x Exp 1 28.014 28.014 7.209 0.012  
Residual 28 108.813 3.886    
Total 31 357.832 11.543    
       
       
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor.      
       
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = 0.012)       
       
Power of performed test with alpha = 0.0500:  for Model : 1.000       
Power of performed test with alpha = 0.0500:  for Exp : 1.000       
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.676     
  
       
Least square means for Model :        
Group Mean      
LZ 14.277      
OZ 10.455      
Std Err of LS Mean = 0.493       
       
Least square means for Exp :        
Group Mean      
C 10.562      
OL 14.17      
Std Err of LS Mean = 0.493       
       
Least square means for Model x Exp :        
Group Mean      
LZ x C 11.538      
LZ x OL 17.017      
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OZ x C 9.587      
OZ x OL 11.323      
Std Err of LS Mean = 0.697       
       
       
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
    
       
Comparisons for factor: Model       
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 3.822 2 7.756 <0.001 Yes  
       
       
Comparisons for factor: Exp       
Comparison Diff of Means p q P P<0.050  
OL vs. C 3.608 2 7.32 <0.001 Yes  
       
       
Comparisons for factor: Exp within LZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 5.479 2 7.861 <0.001 Yes  
       
       
Comparisons for factor: Exp within OZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 1.736 2 2.491 0.089 No  
       
       
Comparisons for factor: Model within C       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 1.951 2 2.799 0.058 No  
       
       
Comparisons for factor: Model within OL       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 5.694 2 8.169 <0.001 Yes 
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Soleus 
Film Properties Report for Calcineurin 
 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                            Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg           Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                 Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  Calcineurin                                  Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit   Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl  
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Calcineurin in Soleus muscle 
Raw IOD values (relative percentage) 
 
   LZ C  LZ OV  OZ C   OZ OV 
6.0 13.3 15.2 16.8 
8.0 10.1 13.3 15.8 
9.6 12.9 11.7 12.5 
12.4 12.1 13.0 14.7 
10.5 13.0 13.8 13.9 
11.0 12.2 11.4 13.3 
5.8 13.2 15.0 16.0 
8.2 10.8 14.1 15.4 
N 8 8 8 8 
Mean 8.9 12.2 13.4 14.8 
Standard Deviation 2.36 1.17 1.41 1.47 
Standard Error of the mean 0.89 0.44 0.53 0.56 
 
LZ C   LZ OV OZ C   OZ OV 
Relative Expression Level 1.00 1.36 1.50 1.66 
Standard error of the mean 0.10 0.05 0.06 0.06 
 
LZ C   LZ OV OZ C   OZ OV 
% RE 100.00 136.40 150.25 165.72 
SE 9.98 4.95 5.96 6.22 
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Statistics 
 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 1:26:35 PM      
       
Data source: Data 1 in Notebook 1       
       
Balanced Design       
       
Dependent Variable: calcineurin        
       
Normality Test: Passed (P = 0.506)     
       
Equal Variance Test: Passed (P = 0.116)     
       
Source of Variation  DF   SS   MS    F    P   
Model 1 101.142 101.142 36.471 <0.001  
Exp 1 42.991 42.991 15.502 <0.001  
Model x Exp 1 6.995 6.995 2.522 0.123  
Residual 28 77.651 2.773    
Total 31 228.778 7.38    
       
       
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure.  
     
       
The difference in the mean values among the different levels of Exp is greater than would be expected by 
chance after allowing for effects of differences in Model.  There is a statistically significant difference (P 
= <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure.  
     
       
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.123)     
  
       
Power of performed test with alpha = 0.0500:  for Model : 1.000       
Power of performed test with alpha = 0.0500:  for Exp : 0.970       
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.209     
  
       
Least square means for Model :        
Group Mean      
LZ 10.564      
OZ 14.12      
Std Err of LS Mean = 0.416       
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Least square means for Exp :        
Group Mean      
C 11.183      
OL 13.501      
Std Err of LS Mean = 0.416       
       
Least square means for Model x Exp :        
Group Mean      
LZ x C 8.938      
LZ x OL 12.191      
OZ x C 13.428      
OZ x OL 14.811      
Std Err of LS Mean = 0.589       
       
       
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
    
       
Comparisons for factor: Model       
Comparison Diff of Means p q P P<0.050  
OZ vs. LZ 3.556 2 8.541 <0.001 Yes  
       
       
Comparisons for factor: Exp       
Comparison Diff of Means p q P P<0.050  
OL vs. C 2.318 2 5.568 <0.001 Yes  
       
       
Comparisons for factor: Exp within LZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 3.253 2 5.525 <0.001 Yes  
       
       
Comparisons for factor: Exp within OZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 1.383 2 2.349 0.108 No  
       
       
Comparisons for factor: Model within C       
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 4.491 2 7.627 <0.001 Yes  
       
       
Comparisons for factor: Model within OL       
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 2.621 2 4.451 0.004 Yes 
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Soleus 
 
Film Properties Report for phospho-Akt 473 
 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                       Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg             Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                         Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  p-Akt 473              Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit   Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl  
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-Akt473 in Soleus muscle 
Raw IOD values (relative percentage) 
 
LZ C   LZ OV OZ C   OZ OV 
%C 13.0 15.5 17.5 14.8 
%C 14.6 14.2 13.8 8.7 
%C 12.5 15.3 17.6 14.7 
%C 15.3 14.2 13.7 8.5 
%C 13.6 15.1 16.1 13.4 
%C 12.2 13.0 15.0 12.0 
%C 14.1 15.1 16.3 13.5 
%C 11.3 15.6 14.7 10.0 
N 8 8 8 8 
Mean 13.6 14.6 15.7 12.2 
Standard Deviation 1.13 0.87 1.61 2.64 
Standard Error of the mean 0.43 0.33 0.61 1.00 
 
LZ C   LZ OV  OZ C   OZ OV 
Relative Expression Level 1.00 1.08 1.15 0.90 
Standard error of the mean 0.03 0.02 0.04 0.07 
 
LZ C   LZ OV  OZ C   OZ OV 
% RE 100.00 107.53 115.49  89.79 
SE 3.14 2.42 4.47 7.33 
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Statistics 
 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 1:29:16 PM      
       
Data source: Data 1 in Notebook 1         
    
Balanced Design       
       
Dependent Variable: p-Akt 473        
       
Normality Test: Passed (P = 0.590)     
       
Equal Variance Test: Failed (P < 0.050)     
       
Source of Variation  DF   SS   MS    F    P   
Model 1 0.58 0.58 0.202 0.657  
Exp 1 9.87 9.87 3.44 0.074  
Model x Exp 1 51.775 51.775 18.045 <0.001  
Residual 28 80.337 2.869    
Total 31 142.562 4.599    
       
       
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor.      
       
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = <0.001)       
       
Power of performed test with alpha = 0.0500:  for Model : 0.0500     
  
Power of performed test with alpha = 0.0500:  for Exp : 0.311       
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.987     
  
       
Least square means for Model :        
Group Mean      
LZ 14.042      
OZ 13.772      
Std Err of LS Mean = 0.423       
       
Least square means for Exp :        
Group Mean      
C 14.462      
OL 13.352      
Std Err of LS Mean = 0.423       
       
Least square means for Model x Exp :        
Group Mean      
LZ x C 13.325      
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LZ x OL 14.758      
OZ x C 15.6      
OZ x OL 11.945      
Std Err of LS Mean = 0.599       
       
       
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
    
       
Comparisons for factor: Model       
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 0.269 2 0.636 0.657 No  
       
       
Comparisons for factor: Exp       
Comparison Diff of Means p q P P<0.050  
C vs. OL 1.111 2 2.623 0.074 No  
       
       
Comparisons for factor: Exp within LZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 1.433 2 2.393 0.102 No  
       
       
Comparisons for factor: Exp within OZ       
Comparison Diff of Means p q P P<0.05  
C vs. OL 3.655 2 6.103 <0.001 Yes  
       
       
Comparisons for factor: Model within C       
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 2.275 2 3.798 0.012 Yes  
       
       
Comparisons for factor: Model within OL       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 2.813 2 4.697 0.003 Yes  
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Soleus 
 
Film Properties Report for phospho-Akt 308 
 
Experimenter:  Anil K Gutta 
 
Muscle / Tissue:  Soleus                                         Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg               Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                           Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  p-Akt 308                Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C                 Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit     Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp                Medium:  5% milk in TBS-T 
Exposure Time:  1min                 Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl  
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-Akt308 in Soleus muscle 
Raw IOD values (relative percentage) 
 
         LZ C   LZ OV OZ C   OZ OV 
%C 13.2 16.2 14.9 13.8 
%C 11.0 13.6 12.9 16.6 
%C 12.5 15.8 14.0 13.0 
%C 12.2 16.8 14.9 13.2 
%C 11.7 16.9 17.3 15.6 
%C 11.1 13.0 13.5 13.3 
%C 11.9 16.3 16.9 15.8 
%C 11.3 13.3 13.4 13.7 
N 8 8 8 8 
Mean 11.9 15.2 14.7 14.4 
Standard Deviation 0.75 1.66 1.63 1.42 
Standard Error of the mean 0.28 0.63 0.62 0.53 
 
LZ C   LZ OV  OZ C   OZ OV 
Relative Expression Level 1.00 1.29 1.24 1.21 
Standard error of the mean 0.02 0.05 0.05 0.05 
 
              LZ C    LZ OV  OZ C   OZ OV 
% RE 100.00 128.55 123.98 121.16 
                                                     SE 2.40 5.30 5.19 4.51 
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Statistics 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 1:32:48 PM     
  
        
Data source: Data 1 in Notebook 1        
        
Balanced Design        
        
Dependent Variable: p Akt 308         
        
Normality Test: Passed (P = 0.240)      
        
Equal Variance Test: Passed (P = 0.424)      
        
Source of Variation  DF   SS   MS    F    P    
Model 1 7.753 7.753 3.881 0.059   
Exp 1 18.629 18.629 9.326 0.005   
Model x Exp 1 27.696 27.696 13.865 <0.001   
Residual 28 55.932 1.998     
Total 31 110.01 3.549     
        
        
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor.     
  
        
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = <0.001)      
  
        
Power of performed test with alpha = 0.0500:  for Model : 0.360      
  
Power of performed test with alpha = 0.0500:  for Exp : 0.809      
  
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.949     
   
        
Least square means for Model :         
Group Mean       
LZ 13.556       
OZ 14.54       
Std Err of LS Mean = 0.353        
        
Least square means for Exp :         
Group Mean       
C 13.285       
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OL 14.811       
Std Err of LS Mean = 0.353        
        
Least square means for Model x Exp :         
Group Mean       
LZ x C 11.863       
LZ x OL 15.249       
OZ x C 14.708       
OZ x OL 14.373       
Std Err of LS Mean = 0.500        
        
        
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
     
        
Comparisons for factor: Model        
Comparison Diff of Means p q P P<0.050   
OZ vs. LZ 0.984 2 2.786 0.059 No   
        
        
Comparisons for factor: Exp        
Comparison Diff of Means p q P P<0.050   
OL vs. C 1.526 2 4.319 0.005 Yes   
        
        
Comparisons for factor: Exp within LZ        
Comparison Diff of Means p q P P<0.05   
OL vs. C 3.387 2 6.777 <0.001 Yes   
        
        
Comparisons for factor: Exp within OZ        
Comparison Diff of Means p q P P<0.05   
C vs. OL 0.335 2 0.67 0.64 No   
        
        
Comparisons for factor: Model within C        
Comparison Diff of Means p q P P<0.05   
OZ vs. LZ 2.845 2 5.694 <0.001 Yes   
        
        
Comparisons for factor: Model within OL        
Comparison Diff of Means p q P P<0.05   
LZ vs. OZ 0.876 2 1.754 0.225 No  
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Soleus 
 
Film Properties Report for phospho-Gsk3β 
 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                            Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg           Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                 Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  p- Gsk3β              Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit   Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl 
Lane 2:  Mol Wt Marker  8 µl  
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-Gsk3β in Soleus muscle 
Raw IOD values (relative percentage) 
 
       LZ C   LZ OV  OZ C   OZ OV 
7.8 10.6 10.6 6.6 
8.7 14.6 18.9 12.5 
7.7 10.4 10.5 6.3 
8.6 14.9 19.5 12.5 
9.9 9.9 11.2 9.0 
10.8 12.1 14.9 12.6 
9.9 10.0 11.2 8.8 
10.8 12.0 14.9 12.8 
N 16 16 16 16 
Mean 9.3 11.8 14.0 10.1 
Standard Deviation 1.25 2.00 3.68 2.79 
Standard Error of the mean 0.32 0.52 0.95 0.72 
 
                                         LZ C   LZ OV OZ C   OZ OV 
Relative Expression Level 1.00 1.27 1.50 1.09 
Standard error of the mean 0.03 0.06 0.10 0.08 
 
LZ C   LZ OV OZ C   OZ OV 
% RE 100.00 127.40 150.43 109.30 
SE 3.47 5.57 10.25 7.78 
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Statistics 
 
Two Way Analysis of Variance Thursday, July 03, 2008, 4:27:37 PM      
       
Data source: Data 1 in Notebook 1       
       
Balanced Design       
       
Dependent Variable: p Gsk3beta        
       
Normality Test: Passed (P = 0.474)     
       
Equal Variance Test: Failed (P < 0.050)     
       
Source of Variation  DF   SS   MS    F    P   
Model 1 17.982 17.982 2.671 0.113  
Exp 1 3.245 3.245 0.482 0.493  
Model x Exp 1 80.809 80.809 12.004 0.002  
Residual 28 188.495 6.732    
Total 31 290.53 9.372    
       
       
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor.      
       
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = 0.002)       
       
Power of performed test with alpha = 0.0500:  for Model : 0.225       
Power of performed test with alpha = 0.0500:  for Exp : 0.0500       
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.910     
  
       
Least square means for Model :        
Group Mean      
LZ 10.546      
OZ 12.045      
Std Err of LS Mean = 0.649       
       
Least square means for Exp :        
Group Mean      
C 11.614      
OL 10.977      
Std Err of LS Mean = 0.649       
       
Least square means for Model x Exp :        
Group Mean      
LZ x C 9.275      
LZ x OL 11.816      
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OZ x C 13.952      
OZ x OL 10.137      
Std Err of LS Mean = 0.917       
       
       
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :   
    
       
Comparisons for factor: Model       
Comparison Diff of Means p q P P<0.050  
OZ vs. LZ 1.499 2 2.311 0.114 No  
       
       
Comparisons for factor: Exp       
Comparison Diff of Means p q P P<0.050  
C vs. OL 0.637 2 0.982 0.493 No  
       
       
Comparisons for factor: Exp within LZ       
Comparison Diff of Means p q P P<0.05  
OL vs. C 2.541 2 2.77 0.06 No  
       
       
Comparisons for factor: Exp within OZ       
Comparison Diff of Means p q P P<0.05  
C vs. OL 3.815 2 4.159 0.007 Yes  
       
       
Comparisons for factor: Model within C       
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 4.677 2 5.099 0.001 Yes  
       
       
Comparisons for factor: Model within OL       
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 1.679 2 1.83 0.206 No 
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Soleus 
 
Film Properties Report for p-p70s6k 
 
Experimenter:  Anil K Gutta 
Muscle / Tissue:  Soleus                                            Species:  Rat (Zucker)  
Protein conc.: 2.0µg/µl x 20µl = 40 µg           Gel type:  10% Tris-HCL SDS_PAGE 
Electrophoresis Voltage:  124V                 Transfer Voltage:  24V   Duration:  45 min 
Primary Antibody:  p- p70s6k             Primary Antibody Dilution:  1:1000 
Incubation Time:  overnight @ 4°C               Medium:  5% BSA in TBS-T 
Secondary Antibody:  Anti-Rabbit   Secondary Antibody Dilution:1:1000 
Incubation Time:  1hr@room temp              Medium:  5% milk in TBS-T 
Exposure Time:  1min                Molecular weight:  60 kDa 
Lane 1:  Biotinylated Ladder 16µl  
Lane 2:  Mol Wt Marker  8 µl 
Lane 3:  Lean Zucker control 20 µl 
Lane 4:  Lean Zucker  Over load 20 µl 
Lane 5:  Obese Zucker control 20 µl  
Lane 6:  Obese Zucker Over load 20 µl 
Lane 7:  Lean Zucker control 20 µl 
Lane 8:  Lean Zucker  Over load 20 µl  
Lane 9:  Obese Zucker control 20 µl  
Lane 10:  Obese Zucker Over load 20 µl  
Lane11:  Positive Control [L6 + IGF Lysate, 3T3 Cell Extract (untreated) 3T3 cell extract  
               (serum treated)HeLa cell lysate] 16 µl 
Lane 12:  Mol Wt Marker 8 µl 
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Phospho-p70s6k in Soleus muscle 
Raw IOD values (relative percentage) 
 
           LZ C   LZ OV   OZ C   OZ OV 
%C 12.9 13.6 12.9 11.1 
%C 12.5 13.3 12.1 9.4 
%C 11.9 14.5 13.2 11.3 
%C 11.9 13.5 12.5 9.8 
%C 12.0 13.4 12.6 11.2 
%C 12.8 13.5 12.6 10.3 
%C 13.6 14.8 11.8 10.1 
%C 11.4 13.9 13.0 9.9 
N 8 8 8 8 
Mean 12.4 13.8 12.6 10.4 
Standard Deviation 0.71 0.56 0.45 0.72 
Standard Error of the mean 0.27 0.21 0.17 0.27 
 
                                           LZ C   LZ OV   OZ C   OZ OV 
Relative Expression Level 1.00 1.11 1.02 0.84 
Standard error of the mean 0.02 0.02 0.01 0.02 
 
          LZ C   LZ OV  OZ C   OZ OV 
% RE 100.00 111.45 101.66 84.03 
SE 2.16 1.72 1.36 2.20 
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Statistics 
 
 
 
Two Way Analysis of Variance Sunday, July 06, 2008, 1:42:06 PM 
 
Data source: Data 1 in Notebook 1 
 
Balanced Design 
 
Dependent Variable: p-p70s6k  
 
Normality Test: Passed (P = 0.255) 
 
Equal Variance Test: Passed (P = 0.466) 
 
Source of Variation  DF   SS   MS    F    P   
Model 1 20.329 20.329 52.865 <0.001  
Exp 1 1.168 1.168 3.038 0.092  
Model x Exp 1 25.908 25.908 67.374 <0.001  
Residual 28 10.767 0.385    
Total 31 58.173 1.877    
 
 
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor. 
 
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = <0.001) 
 
Power of performed test with alpha = 0.0500:  for Model : 1.000 
Power of performed test with alpha = 0.0500:  for Exp : 0.266 
Power of performed test with alpha = 0.0500:  for Model x Exp : 1.000 
 
Least square means for Model :  
Group Mean  
LZ 13.084  
OZ 11.490  
Std Err of LS Mean = 0.155 
 
Least square means for Exp :  
Group Mean  
C 12.478  
OL 12.096  
Std Err of LS Mean = 0.155 
 
Least square means for Model x Exp :  
Group Mean  
LZ x C 12.375  
LZ x OL 13.792  
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OZ x C 12.581  
OZ x OL 10.399  
Std Err of LS Mean = 0.219 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Model 
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 1.594 2 10.283 <0.001 Yes  
 
 
Comparisons for factor: Exp 
Comparison Diff of Means p q P P<0.050  
C vs. OL 0.382 2 2.465 0.092 No  
 
 
Comparisons for factor: Exp within LZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 1.417 2 6.465 <0.001 Yes  
 
 
Comparisons for factor: Exp within OZ 
Comparison Diff of Means p q P P<0.05  
C vs. OL 2.182 2 9.951 <0.001 Yes  
 
 
Comparisons for factor: Model within C 
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 0.206 2 0.937 0.513 No  
 
 
Comparisons for factor: Model within OL 
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 3.394 2 15.479 <0.001 Yes  
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Statistics 
 
Soleus wet weight 
 
Two Way Analysis of Variance Wednesday, July 09, 2008, 2:54:55 PM 
 
Data source: Data 1 in Notebook 1 
 
Balanced Design 
 
Dependent Variable: Sol WW  
 
Normality Test: Passed (P = 0.343) 
 
Equal Variance Test: Passed (P = 0.380) 
 
Source of Variation  DF   SS   MS    F    P   
Model 1 12054.050 12054.050 22.066 <0.001  
Exp 1 31920.050 31920.050 58.432 <0.001  
Model x Exp 1 3511.250 3511.250 6.428 0.022  
Residual 16 8740.400 546.275   
Total 19 56225.750 2959.250    
 
 
Main effects cannot be properly interpreted if significant interaction is determined. This is because the 
size of a factor's effect depends upon the level of the other factor. 
 
The effect of different levels of Model depends on what level of Exp is present.  There is a statistically 
significant interaction between Model and Exp.  (P = 0.022) 
 
Power of performed test with alpha = 0.0500:  for Model : 0.995 
Power of performed test with alpha = 0.0500:  for Exp : 1.000 
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.588 
 
Least square means for Model :  
Group Mean  
LZ 238.800 
OZ 189.700 
Std Err of LS Mean = 7.391 
 
Least square means for Exp :  
Group Mean  
C 174.300 
OL 254.200 
Std Err of LS Mean = 7.391 
 
 
Least square means for Model x Exp :  
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Group Mean  
LZ x C 185.600 
LZ x OL 292.000 
OZ x C 163.000 
OZ x OL 216.400 
Std Err of LS Mean = 10.453 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Model 
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 49.100 2 6.643 <0.001 Yes  
 
 
Comparisons for factor: Exp 
Comparison Diff of Means p q P P<0.050  
OL vs. C 79.900 2 10.810 <0.001 Yes  
 
 
Comparisons for factor: Exp within LZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 106.400 2 10.179 <0.001 Yes  
 
 
Comparisons for factor: Exp within OZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 53.400 2 5.109 0.002 Yes  
 
 
Comparisons for factor: Model within C 
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 22.600 2 2.162 0.146 No  
 
 
Comparisons for factor: Model within OL 
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 75.600 2 7.233 <0.001 Yes  
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Statistics 
 
 
Fiber cross sectional area (FCA) 
 
Two Way Analysis of Variance Wednesday, July 09, 2008, 3:01:54 PM 
 
Data source: Data 1 in Notebook 1 
 
Balanced Design 
 
Dependent Variable: FCA  
 
Normality Test: Passed (P = 0.357) 
 
Equal Variance Test: Failed (P < 0.050) 
 
Source of Variation  DF   SS   MS    F    P   
Model 1 1408702.296 1408702.296 4.339 0.048  
Exp 1 1693383.850 1693383.850 5.216 0.032  
Model x Exp 1 985342.946 985342.946 3.035 0.094  
Residual 24 7791070.178 324627.924    
Total 27 11878499.271 439944.417    
 
 
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= 0.048).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of Exp is greater than would be expected by 
chance after allowing for effects of differences in Model.  There is a statistically significant difference (P 
= 0.032).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
 
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.094) 
 
Power of performed test with alpha = 0.0500:  for Model : 0.406 
Power of performed test with alpha = 0.0500:  for Exp : 0.496 
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.263 
 
Least square means for Model:  
Group Mean  
LZ 3999.937  
OZ 4448.538  
Std Err of LS Mean = 152.275 
 
Least square means for Exp:  
Group Mean  
C 3978.315  
OL 4470.160  
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Std Err of LS Mean = 152.275 
 
Least square means for Model x Exp:  
Group Mean  
LZ x C 3566.422  
LZ x OL 4433.452  
OZ x C 4390.208  
OZ x OL 4506.869  
Std Err of LS Mean = 215.350 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Model 
Comparison Diff of Means p q P P<0.050  
OZ vs. LZ 448.601 2 2.946 0.048 Yes  
 
 
Comparisons for factor: Exp 
Comparison Diff of Means p q P P<0.050  
OL vs. C 491.845 2 3.230 0.032 Yes  
 
 
Comparisons for factor: Exp within LZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 867.030 2 4.026 0.009 Yes  
 
 
Comparisons for factor: Exp within OZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 116.661 2 0.542 0.705 No  
 
 
Comparisons for factor: Model within C 
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 823.786 2 3.825 0.013 Yes  
 
 
Comparisons for factor: Model within OL 
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 73.417 2 0.341 0.812 No 
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Statistics 
 
 
Whole Muscle Cross Sectional Area 
 
Two Way Analysis of Variance Friday, July 18, 2008, 12:55:01 PM     
      
Data source: Data 1 in Notebook 1      
      
Balanced Design      
      
Dependent Variable: MCA       
      
Normality Test: Passed (P = 0.864)    
      
Equal Variance Test: Passed (P = 0.269)    
      
Source of Variation  DF   SS   MS    F    P  
Model 1 51.138 51.138 9.906 0.006 
Exp 1 150.872 150.872 29.227 <0.001 
Model x Exp 1 9.936 9.936 1.925 0.184 
Residual 16 82.594 5.162   
Total 19 294.54 15.502   
      
      
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= 0.006).  To isolate which group(s) differ from the others use a multiple comparison procedure.  
    
      
The difference in the mean values among the different levels of Exp is greater than would be expected by 
chance after allowing for effects of differences in Model.  There is a statistically significant difference (P 
= <0.001).  To isolate which group(s) differ from the others use a multiple comparison procedure.  
    
      
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.184)      
      
Power of performed test with alpha = 0.0500:  for Model : 0.812      
Power of performed test with alpha = 0.0500:  for Exp : 1.000      
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.139      
      
Least square means for Model:       
Group Mean     
LZ 19.749     
OZ 16.551     
Std Err of LS Mean = 0.718      
      
Least square means for Exp :       
Group Mean     
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C 15.403     
OL 20.896     
Std Err of LS Mean = 0.718      
      
Least square means for Model x Exp:       
Group Mean     
LZ x C 16.297     
LZ x OL 23.2     
OZ x C 14.509     
OZ x OL 18.592     
Std Err of LS Mean = 1.016      
      
      
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):      
Overall significance level = 0.05     
      
Comparisons for factor: Model      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
LZ vs. OZ 3.198 3.147 0.00623 0.05 Yes 
      
      
Comparisons for factor: Exp      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
OL vs. C 5.493 5.406 0.0000582 0.05 Yes 
      
      
Comparisons for factor: Exp within LZ      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
OL vs. C 6.903 4.804 0 0.05 Yes 
      
      
Comparisons for factor: Exp within OZ      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
OL vs. C 4.083 2.842 0.012 0.05 Yes 
      
      
Comparisons for factor: Model within C      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
LZ vs. OZ 1.788 1.245 0.231 0.05 No 
      
      
Comparisons for factor: Model within OL      
Comparison Diff of Means t Unadjusted P Critical Level Significant? 
LZ vs. OZ 4.608 3.207 0.006 0.05 Yes 
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Statistics 
 
 
Myosin heavy chain (MHC) Type I 
 
Two Way Analysis of Variance Wednesday, July 09, 2008, 3:08:27 PM 
 
Data source: Data 1 in Notebook 1 
 
Balanced Design 
 
Dependent Variable: Type I  
 
Normality Test: Passed (P = 0.348) 
 
Equal Variance Test: Passed (P = 0.411) 
 
Source of Variation  DF   SS   MS    F    P   
Model 1 156.250 156.250 6.153 0.029  
Exp 1 76.563 76.563 3.015 0.108  
Model x Exp 1 4.202 4.202 0.165 0.691  
Residual 12 304.725 25.394    
Total 15 541.740 36.116    
 
 
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= 0.029).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of Exp is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Model.  There is not a statistically significant difference (P = 0.108). 
 
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.691) 
 
Power of performed test with alpha = 0.0500:  for Model : 0.547 
Power of performed test with alpha = 0.0500:  for Exp : 0.246 
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.0500 
 
Least square means for Model:  
Group Mean  
LZ 84.625  
OZ 90.875  
Std Err of LS Mean = 1.782 
 
Least square means for Exp:  
Group Mean  
C 85.563  
OL 89.938  
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Std Err of LS Mean = 1.782 
 
Least square means for Model x Exp:  
Group Mean  
LZ x C 81.925  
LZ x OL 87.325  
OZ x C 89.200  
OZ x OL 92.550  
Std Err of LS Mean = 2.520 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Model 
Comparison Diff of Means p q P P<0.050  
OZ vs. LZ 6.250 2 3.508 0.029 Yes  
 
 
Comparisons for factor: Exp 
Comparison Diff of Means p q P P<0.050  
OL vs. C 4.375 2 2.456 0.108 No  
 
 
Comparisons for factor: Exp within LZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 5.400 2 2.143 0.156 No  
 
 
Comparisons for factor: Exp within OZ 
Comparison Diff of Means p q P P<0.05  
OL vs. C 3.350 2 1.330 0.366 No  
 
 
Comparisons for factor: Model within C 
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 7.275 2 2.887 0.064 No  
 
 
Comparisons for factor: Model within OL 
Comparison Diff of Means p q P P<0.05  
OZ vs. LZ 5.225 2 2.074 0.168 No  
 
t-test Wednesday, July 09, 2008, 3:14:35 PM 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.454) 
 
Equal Variance Test: Failed (P < 0.050) 
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Test execution ended by user request, Rank Sum Test begun 
 
Mann-Whitney Rank Sum Test Wednesday, July 09, 2008, 3:14:35 PM 
 
Data source: Data 1 in Notebook 1 
 
Group N  Missing Median    25%      75%     
LZ con 5 0 77.800 72.800 87.175  
LZ OL 4 0 87.700 85.200 89.450  
 
Mann-Whitney U Statistic= 4.000 
 
T = 26.000  n(small)= 4  n(big)= 5  P(est.)= 0.178  P(exact)= 0.190 
 
The difference in the median values between the two groups is not great enough to exclude the possibility 
that the difference is due to random sampling variability; there is not a statistically significant difference  
(P = 0.190) 
 
t-test Wednesday, July 09, 2008, 3:21:47 PM 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.366) 
 
Equal Variance Test: Passed (P = 0.723) 
 
Group Name  N  Missing Mean Std Dev SEM  
OZ con 5 0 88.660 2.660 1.189  
OZ OL 4 0 92.550 6.608 3.304  
 
Difference -3.890 
 
t = -1.216  with 7 degrees of freedom. (P = 0.264) 
 
95 percent confidence interval for difference of means: -11.457 to 3.677 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the 
difference is due to random sampling variability. There is not a statistically significant difference between 
the input groups (P = 0.264). 
 
Power of performed test with alpha = 0.050: 0.089 
 
The power of the performed test (0.089) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously. 
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Statistics 
 
 
Myosin heavy chain (MHC) Type II 
 
Two Way Analysis of Variance Wednesday, July 09, 2008, 3:17:55 PM 
 
Data source: Data 1 in Notebook 1 
 
Balanced Design 
 
Dependent Variable: Type II  
 
Normality Test: Passed (P = 0.348) 
 
Equal Variance Test: Passed (P = 0.411) 
 
Source of Variation  DF   SS   MS    F    P   
Model 1 156.250 156.250 6.153 0.029  
Exp 1 76.562 76.562 3.015 0.108  
Model x Exp 1 4.203 4.203 0.165 0.691  
Residual 12 304.725 25.394    
Total 15 541.740 36.116    
 
 
The difference in the mean values among the different levels of Model is greater than would be expected 
by chance after allowing for effects of differences in Exp.  There is a statistically significant difference (P 
= 0.029).  To isolate which group(s) differ from the others use a multiple comparison procedure. 
 
The difference in the mean values among the different levels of Exp is not great enough to exclude the 
possibility that the difference is just due to random sampling variability after allowing for the effects of 
differences in Model.  There is not a statistically significant difference (P = 0.108). 
 
The effect of different levels of Model does not depend on what level of Exp is present.  There is not a 
statistically significant interaction between Model and Exp.  (P = 0.691) 
 
Power of performed test with alpha = 0.0500:  for Model : 0.547 
Power of performed test with alpha = 0.0500:  for Exp : 0.246 
Power of performed test with alpha = 0.0500:  for Model x Exp : 0.0500 
 
Least square means for Model:  
Group Mean  
LZ 15.375  
OZ 9.125  
Std Err of LS Mean = 1.782 
 
Least square means for Exp:  
Group Mean  
C 14.438  
OL 10.063  
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Std Err of LS Mean = 1.782 
 
Least square means for Model x Exp:  
Group Mean  
LZ x C 18.075  
LZ x OL 12.675  
OZ x C 10.800  
OZ x OL 7.450  
Std Err of LS Mean = 2.520 
 
 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
 
Comparisons for factor: Model 
Comparison Diff of Means p q P P<0.050  
LZ vs. OZ 6.250 2 3.508 0.029 Yes  
 
 
Comparisons for factor: Exp 
Comparison Diff of Means p q P P<0.050  
C vs. OL 4.375 2 2.456 0.108 No  
 
 
Comparisons for factor: Exp within LZ 
Comparison Diff of Means p q P P<0.05  
C vs. OL 5.400 2 2.143 0.156 No  
 
 
Comparisons for factor: Exp within OZ 
Comparison Diff of Means p q P P<0.05  
C vs. OL 3.350 2 1.330 0.366 No  
 
 
Comparisons for factor: Model within C 
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 7.275 2 2.887 0.064 No  
 
 
Comparisons for factor: Model within OL 
Comparison Diff of Means p q P P<0.05  
LZ vs. OZ 5.225 2 2.074 0.168 No  
 
t-test Wednesday, July 09, 2008, 3:24:07 PM 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.738) 
 
Equal Variance Test: Failed (P < 0.050) 
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Test execution ended by user request, Rank Sum Test begun 
 
Mann-Whitney Rank Sum Test Wednesday, July 09, 2008, 3:24:07 PM 
 
Data source: Data 1 in Notebook 1 
 
Group N  Missing  Median    25%     75%    
LZ con 4 0 17.650 12.550 23.600  
LZ OL 4 0 12.300 10.550 14.800  
 
Mann-Whitney U Statistic= 4.000 
 
T = 22.000  n(small)= 4  n(big)= 4  P(est.)= 0.312  P(exact)= 0.343 
 
The difference in the median values between the two groups is not great enough to exclude the possibility 
that the difference is due to random sampling variability; there is not a statistically significant difference  
(P = 0.343) 
 
t-test Wednesday, July 09, 2008, 3:25:33 PM 
 
Data source: Data 1 in Notebook 1 
 
Normality Test: Passed (P = 0.216) 
 
Equal Variance Test: Passed (P = 0.594) 
 
Group Name  N  Missing Mean Std Dev SEM  
OZ con 4 0 10.800 2.736 1.368  
OZ OL 4 0 7.450 6.608 3.304  
 
Difference 3.350 
 
t = 0.937 with 6 degrees of freedom. (P = 0.385) 
 
95 percent confidence interval for difference of means: -5.401 to 12.101 
 
The difference in the mean values of the two groups is not great enough to reject the possibility that the 
difference is due to random sampling variability. There is not a statistically significant difference between 
the input groups (P = 0.385). 
 
Power of performed test with alpha = 0.050: 0.050 
 
The power of the performed test (0.050) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously. 
 
 
 
 
 
  92  
 
 
 
REFERENCES 
 
1. Adams GR, Haddad F, and Baldwin KM. Time course of changes in markers of 
myogenesis in overloaded rat skeletal muscles. J Appl Physiol 87: 1705-1712, 1999. 
2. Adams GR and McCue SA. Localized infusion of IGF-I results in skeletal muscle 
hypertrophy in rats. J Appl Physiol 84: 1716-1722, 1998. 
3. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, and Hemmings 
BA. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 15: 6541-
6551, 1996. 
4. Alessi DR, Kozlowski MT, Weng QP, Morrice N, and Avruch J. 3-Phosphoinositide-
dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in 
vivo and in vitro. Curr Biol 8: 69-81, 1998. 
5. Allen DL, Linderman JK, Roy RR, Bigbee AJ, Grindeland RE, Mukku V, and 
Edgerton VR. Apoptosis: a mechanism contributing to remodeling of skeletal muscle in 
response to hindlimb unweighting. Am J Physiol 273: C579-587, 1997. 
6. Alway SE, Siu PM, Murlasits Z, and Butler DC. Muscle hypertrophy models: 
applications for research on aging. Can J Appl Physiol 30: 591-624, 2005. 
7. Alway SE, Winchester PK, Davis ME, and Gonyea WJ. Regionalized adaptations and 
muscle fiber proliferation in stretch-induced enlargement. J Appl Physiol 66: 771-781, 
1989. 
8. Andersen NB, Andreassen TT, Orskov H, and Oxlund H. Growth hormone and mild 
exercise in combination increases markedly muscle mass and tetanic tension in old rats. 
Eur J Endocrinol 143: 409-418, 2000. 
9. Antonio J and Gonyea WJ. Muscle fiber splitting in stretch-enlarged avian muscle. Med 
Sci Sports Exerc 26: 973-977, 1994. 
10. Antonio J and Gonyea WJ. Progressive stretch overload of skeletal muscle results in 
hypertrophy before hyperplasia. J Appl Physiol 75: 1263-1271, 1993. 
11. Antonio J and Gonyea WJ. Skeletal muscle fiber hyperplasia. Med Sci Sports Exerc 25: 
1333-1345, 1993. 
12. Ardevol A, Remesar CA, Fernandez-Lopez JA, and Alemany M. Lactate-bicarbonate 
interrelationship during exercise and recovery in lean and obese Zucker rats. Int J Obes 
Relat Metab Disord 21: 333-339, 1997. 
13. Armstrong RB and Ianuzzo CD. Compensatory hypertrophy of skeletal muscle fibers in 
streptozotocin-diabetic rats. Cell Tissue Res 181: 255-266, 1977. 
14. Armstrong RB, Marum P, Tullson P, and Saubert CWt. Acute hypertrophic response of 
skeletal muscle to removal of synergists. J Appl Physiol 46: 835-842, 1979. 
15. Ashmore CR, Lee YB, Summers P, and Hitchcock L. Stretch-induced growth in chicken 
wing muscles: nerve-muscle interaction in muscular dystrophy. Am J Physiol 246: C378-
384, 1984. 
16. Baar K, Blough E, Dineen B, and Esser K. Transcriptional regulation in response to 
exercise. Exerc Sport Sci Rev 27: 333-379, 1999. 
  93  
 
 
17. Baar K and Esser K. Phosphorylation of p70(S6k) correlates with increased skeletal 
muscle mass following resistance exercise. Am J Physiol 276: C120-127, 1999. 
18. Baldi JC and Snowling N. Resistance training improves glycaemic control in obese type 
2 diabetic men. Int J Sports Med 24: 419-423, 2003. 
19. Baldwin KM and Haddad F. Skeletal muscle plasticity: cellular and molecular responses 
to altered physical activity paradigms. Am J Phys Med Rehabil 81: S40-51, 2002. 
20. Baldwin KM, Martinez OM, and Cheadle WG. Enzymatic changes in hypertrophied 
fast-twitch skeletal muscle. Pflugers Arch 364: 229-234, 1976. 
21. Baldwin KM, Valdez V, Herrick RE, MacIntosh AM, and Roy RR. Biochemical 
properties of overloaded fast-twitch skeletal muscle. J Appl Physiol 52: 467-472, 1982. 
22. Barnett JG, Holly RG, and Ashmore CR. Stretch-induced growth in chicken wing 
muscles: biochemical and morphological characterization. Am J Physiol 239: C39-46, 1980. 
23. Berdanier CD. Diet, autoimmunity, and insulin-dependent diabetes mellitus: a 
controversy. Proc Soc Exp Biol Med 209: 223-230, 1995. 
24. Bigard AX, Serrurier B, Merino D, Lienhard F, Berthelot M, and Guezennec CY. 
Myosin heavy chain composition of regenerated soleus muscles during hindlimb 
suspension. Acta Physiol Scand 161: 23-30, 1997. 
25. Blough ER and Linderman JK. Lack of skeletal muscle hypertrophy in very aged male 
Fischer 344 x Brown Norway rats. J Appl Physiol 88: 1265-1270, 2000. 
26. Blough ER, Rennie ER, Zhang F, and Reiser PJ. Enhanced electrophoretic separation 
and resolution of myosin heavy chains in mammalian and avian skeletal muscles. Anal 
Biochem 233: 31-35, 1996. 
27. Bodine SC. mTOR signaling and the molecular adaptation to resistance exercise. Med Sci 
Sports Exerc 38: 1950-1957, 2006. 
28. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, 
Scrimgeour A, Lawrence JC, Glass DJ, and Yancopoulos GD. Akt/mTOR pathway is a 
crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in 
vivo. Nat Cell Biol 3: 1014-1019, 2001. 
29. Bosco C, Tihanyi J, Pucspk J, Kovacs I, Gabossy A, Colli R, Pulvirenti G, Tranquilli C, 
Foti C, Viru M, and Viru A. Effect of oral creatine supplementation on jumping and 
running performance. Int J Sports Med 18: 369-372, 1997. 
30. Broderick TL, Poirier P, and Gillis M. Exercise training restores abnormal myocardial 
glucose utilization and cardiac function in diabetes. Diabetes Metab Res Rev 21: 44-50, 
2005. 
31. Brozinick JT, Jr., Etgen GJ, Jr., Yaspelkis BB, 3rd, Kang HY, and Ivy JL. Effects of 
exercise training on muscle GLUT-4 protein content and translocation in obese Zucker 
rats. Am J Physiol 265: E419-427, 1993. 
32. Bruce CR, Kriketos AD, Cooney GJ, and Hawley JA. Disassociation of muscle 
triglyceride content and insulin sensitivity after exercise training in patients with Type 2 
diabetes. Diabetologia 47: 23-30, 2004. 
33. Caiozzo VJ, Herrick RE, and Baldwin KM. Influence of hyperthyroidism on maximal 
shortening velocity and myosin isoform distribution in skeletal muscles. Am J Physiol 
261: C285-295, 1991. 
34. Cauza E, Hanusch-Enserer U, Strasser B, Ludvik B, Metz-Schimmerl S, Pacini G, 
Wagner O, Georg P, Prager R, Kostner K, Dunky A, and Haber P. The relative benefits 
of endurance and strength training on the metabolic factors and muscle function of 
people with type 2 diabetes mellitus. Arch Phys Med Rehabil 86: 1527-1533, 2005. 
  94  
 
 
35. Chin ER and Allen DG. The role of elevations in intracellular [Ca2+] in the 
development of low frequency fatigue in mouse single muscle fibres. J Physiol 491 (Pt 3): 
813-824, 1996. 
36. Chin ER, Olson EN, Richardson JA, Yang Q, Humphries C, Shelton JM, Wu H, Zhu 
W, Bassel-Duby R, and Williams RS. A calcineurin-dependent transcriptional pathway 
controls skeletal muscle fiber type. Genes Dev 12: 2499-2509, 1998. 
37. Cortez MY, Torgan CE, Brozinick JT, Jr., and Ivy JL. Insulin resistance of obese Zucker 
rats exercise trained at two different intensities. Am J Physiol 261: E613-619, 1991. 
38. Coutant A, Rescan C, Gilot D, Loyer P, Guguen-Guillouzo C, and Baffet G. PI3K-
FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK 
supports both proliferation and survival. Hepatology 36: 1079-1088, 2002. 
39. Crettaz M, Prentki M, Zaninetti D, and Jeanrenaud B. Insulin resistance in soleus 
muscle from obese Zucker rats. Involvement of several defective sites. Biochem J 186: 525-
534, 1980. 
40. Diamond J. The double puzzle of diabetes. Nature 423: 599-602, 2003. 
41. Dufner A and Thomas G. Ribosomal S6 kinase signaling and the control of translation. 
Exp Cell Res 253: 100-109, 1999. 
42. Dunn SE, Burns JL, and Michel RN. Calcineurin is required for skeletal muscle 
hypertrophy. J Biol Chem 274: 21908-21912, 1999. 
43. Dupont-Versteegden EE, Knox M, Gurley CM, Houle JD, and Peterson CA. 
Maintenance of muscle mass is not dependent on the calcineurin-NFAT pathway. Am J 
Physiol Cell Physiol 282: C1387-1395, 2002. 
44. Edgerton VR, Roy RR, Allen DL, and Monti RJ. Adaptations in skeletal muscle disuse 
or decreased-use atrophy. Am J Phys Med Rehabil 81: S127-147, 2002. 
45. Eriksson JG. Exercise and the treatment of type 2 diabetes mellitus. An update. Sports 
Med 27: 381-391, 1999. 
46. Esser KA and White TP. Mechanical load affects growth and maturation of skeletal 
muscle grafts. J Appl Physiol 78: 30-37, 1995. 
47. Etgen GJ, Jr., Wilson CM, Jensen J, Cushman SW, and Ivy JL. Glucose transport and 
cell surface GLUT-4 protein in skeletal muscle of the obese Zucker rat. Am J Physiol 271: 
E294-301, 1996. 
48. Farrell PA, Fedele MJ, Hernandez J, Fluckey JD, Miller JL, 3rd, Lang CH, Vary TC, 
Kimball SR, and Jefferson LS. Hypertrophy of skeletal muscle in diabetic rats in 
response to chronic resistance exercise. J Appl Physiol 87: 1075-1082, 1999. 
49. Feldman EB. Creatine: a dietary supplement and ergogenic aid. Nutr Rev 57: 45-50, 1999. 
50. Florini JR. Hormonal control of muscle growth. Muscle Nerve 10: 577-598, 1987. 
51. Florini JR, Ewton DZ, Falen SL, and Van Wyk JJ. Biphasic concentration dependency 
of stimulation of myoblast differentiation by somatomedins. Am J Physiol 250: C771-778, 
1986. 
52. Fluckey JD, Pohnert SC, Boyd SG, Cortright RN, Trappe TA, and Dohm GL. Insulin 
stimulation of muscle protein synthesis in obese Zucker rats is not via a rapamycin-
sensitive pathway. Am J Physiol Endocrinol Metab 279: E182-187, 2000. 
53. Frey N, Richardson JA, and Olson EN. Calsarcins, a novel family of sarcomeric 
calcineurin-binding proteins. Proc Natl Acad Sci U S A 97: 14632-14637, 2000. 
54. Friedman JE, Sherman WM, Reed MJ, Elton CW, and Dohm GL. Exercise training 
increases glucose transporter protein GLUT-4 in skeletal muscle of obese Zucker (fa/fa) 
rats. FEBS Lett 268: 13-16, 1990. 
  95  
 
 
55. Gautsch TA, Kandl SM, Donovan SM, and Layman DK. Growth hormone promotes 
somatic and skeletal muscle growth recovery in rats following chronic protein-energy 
malnutrition. J Nutr 129: 828-837, 1999. 
56. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 9: 344-350, 
2003. 
57. Gollnick PD, Parsons D, Riedy M, and Moore RL. Fiber number and size in overloaded 
chicken anterior latissimus dorsi muscle. J Appl Physiol 54: 1292-1297, 1983. 
58. Greene JG and Timbury GC. A geriatric psychiatry day hospital service: a five-year 
review. Age Ageing 8: 49-53, 1979. 
59. Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, Woodgett J, 
Kilter H, and Force T. Stabilization of beta-catenin by a Wnt-independent mechanism 
regulates cardiomyocyte growth. Proc Natl Acad Sci U S A 100: 4610-4615, 2003. 
60. Hei YJ, Chen X, Pelech SL, Diamond J, and McNeill JH. Skeletal muscle mitogen-
activated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats 
and reversal by vanadium. Diabetes 44: 1147-1155, 1995. 
61. Hennig R and Lomo T. Gradation of force output in normal fast and slow muscles of the 
rat. Acta Physiol Scand 130: 133-142, 1987. 
62. Henriksen EJ. Invited review: Effects of acute exercise and exercise training on insulin 
resistance. J Appl Physiol 93: 788-796, 2002. 
63. Henriksen EJ and Jacob S. Effects of captopril on glucose transport activity in skeletal 
muscle of obese Zucker rats. Metabolism 44: 267-272, 1995. 
64. Holly RG, Barnett JG, Ashmore CR, Taylor RG, and Mole PA. Stretch-induced growth 
in chicken wing muscles: a new model of stretch hypertrophy. Am J Physiol 238: C62-71, 
1980. 
65. Holten MK, Zacho M, Gaster M, Juel C, Wojtaszewski JF, and Dela F. Strength 
training increases insulin-mediated glucose uptake, GLUT4 content, and insulin 
signaling in skeletal muscle in patients with type 2 diabetes. Diabetes 53: 294-305, 2004. 
66. Honkola A, Forsen T, and Eriksson J. Resistance training improves the metabolic 
profile in individuals with type 2 diabetes. Acta Diabetol 34: 245-248, 1997. 
67. Ianuzzo CD and Chen V. Metabolic character of hypertrophied rat muscle. J Appl 
Physiol 46: 738-742, 1979. 
68. Ishihara A, Roy RR, Ohira Y, and Edgerton VR. Motoneuron and sensory neuron 
plasticity to varying neuromuscular activity levels. Exerc Sport Sci Rev 31: 51-57, 2003. 
69. Ivy JL, Brozinick JT, Jr., Torgan CE, and Kastello GM. Skeletal muscle glucose 
transport in obese Zucker rats after exercise training. J Appl Physiol 66: 2635-2641, 1989. 
70. Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, Dietze GJ, and Henriksen 
EJ. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in 
insulin-resistant rat skeletal muscle. Diabetes 45: 1024-1029, 1996. 
71. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, and Thomas G. 
Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. Embo J 
16: 3693-3704, 1997. 
72. Juel C, Holten MK, and Dela F. Effects of strength training on muscle lactate release 
and MCT1 and MCT4 content in healthy and type 2 diabetic humans. J Physiol 556: 297-
304, 2004. 
73. Kamber M, Koster M, Kreis R, Walker G, Boesch C, and Hoppeler H. Creatine 
supplementation--part I: performance, clinical chemistry, and muscle volume. Med Sci 
Sports Exerc 31: 1763-1769, 1999. 
  96  
 
 
74. Kami K and Senba E. In vivo activation of STAT3 signaling in satellite cells and 
myofibers in regenerating rat skeletal muscles. J Histochem Cytochem 50: 1579-1589, 2002. 
75. Kandarian SC and White TP. Mechanical deficit persists during long-term muscle 
hypertrophy. J Appl Physiol 69: 861-867, 1990. 
76. Kandarian SC and Williams JH. Contractile properties of skinned fibers from 
hypertrophied skeletal muscle. Med Sci Sports Exerc 25: 999-1004, 1993. 
77. King PA, Horton ED, Hirshman MF, and Horton ES. Insulin resistance in obese Zucker 
rat (fa/fa) skeletal muscle is associated with a failure of glucose transporter 
translocation. J Clin Invest 90: 1568-1575, 1992. 
78. Kirby CR, Ryan MJ, and Booth FW. Eccentric exercise training as a countermeasure to 
non-weight-bearing soleus muscle atrophy. J Appl Physiol 73: 1894-1899, 1992. 
79. Koopman R, Zorenc AH, Gransier RJ, Cameron-Smith D, and van Loon LJ. Increase in 
S6K1 phosphorylation in human skeletal muscle following resistance exercise occurs 
mainly in type II muscle fibers. Am J Physiol Endocrinol Metab 290: E1245-1252, 2006. 
80. Lai KM, Gonzalez M, Poueymirou WT, Kline WO, Na E, Zlotchenko E, Stitt TN, 
Economides AN, Yancopoulos GD, and Glass DJ. Conditional activation of akt in adult 
skeletal muscle induces rapid hypertrophy. Mol Cell Biol 24: 9295-9304, 2004. 
81. Linderman JK and Blough ER. Aging does not attenuate plantaris muscle hypertrophy 
in male Fischer 344 rats. Med Sci Sports Exerc 34: 1115-1119, 2002. 
82. Liu Y, Cseresnyes Z, Randall WR, and Schneider MF. Activity-dependent nuclear 
translocation and intranuclear distribution of NFATc in adult skeletal muscle fibers. J 
Cell Biol 155: 27-39, 2001. 
83. Loughna PT and Bates PC. Interactions between growth hormone and nutrition in 
hypophysectomised rats: skeletal muscle myosin heavy chain mRNA levels. Biochem 
Biophys Res Commun 198: 97-102, 1994. 
84. Lowe DA and Alway SE. Animal models for inducing muscle hypertrophy: are they 
relevant for clinical applications in humans? J Orthop Sports Phys Ther 32: 36-43, 2002. 
85. Markuns JF, Napoli R, Hirshman MF, Davalli AM, Cheatham B, and Goodyear LJ. 
Effects of streptozocin-induced diabetes and islet cell transplantation on insulin 
signaling in rat skeletal muscle. Endocrinology 140: 106-111, 1999. 
86. McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B, and Goldspink G. 
Expression of insulin growth factor-1 splice variants and structural genes in rabbit 
skeletal muscle induced by stretch and stimulation. J Physiol 516 (Pt 2): 583-592, 1999. 
87. Melian E, Gonzalez B, Ajo R, Gonzalez N, and Sanchez Franco F. Tissue-specific 
response of IGF-I mRNA expression to obesity-associated GH decline in the male 
Zucker fatty rat. J Endocrinol 160: 49-56, 1999. 
88. Mitchell PO and Pavlath GK. A muscle precursor cell-dependent pathway contributes 
to muscle growth after atrophy. Am J Physiol Cell Physiol 281: C1706-1715, 2001. 
89. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, and 
Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. 
Cell 93: 215-228, 1998. 
90. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, and Weiser-Evans 
MC. Unique, highly proliferative growth phenotype expressed by embryonic and 
neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K 
signaling and is actively repressed by PTEN. Circulation 109: 1299-1306, 2004. 
  97  
 
 
91. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton 
ER, Sweeney HL, and Rosenthal N. Localized Igf-1 transgene expression sustains 
hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27: 195-200, 2001. 
92. Nader GA and Esser KA. Intracellular signaling specificity in skeletal muscle in 
response to different modes of exercise. J Appl Physiol 90: 1936-1942, 2001. 
93. Ohira Y. Effects of denervation and deafferentation on mass and enzyme activity in rat 
skeletal muscles. Jpn J Physiol 39: 21-31, 1989. 
94. Olson EN and Williams RS. Remodeling muscles with calcineurin. Bioessays 22: 510-519, 
2000. 
95. Pallafacchina G, Calabria E, Serrano AL, Kalhovde JM, and Schiaffino S. A protein 
kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth 
but not fiber type specification. Proc Natl Acad Sci U S A 99: 9213-9218, 2002. 
96. Panton LB, Rathmacher JA, Baier S, and Nissen S. Nutritional supplementation of the 
leucine metabolite beta-hydroxy-beta-methylbutyrate (hmb) during resistance training. 
Nutrition 16: 734-739, 2000. 
97. Parkington JD, LeBrasseur NK, Siebert AP, and Fielding RA. Contraction-mediated 
mTOR, p70S6k, and ERK1/2 phosphorylation in aged skeletal muscle. J Appl Physiol 97: 
243-248, 2004. 
98. Parkington JD, Siebert AP, LeBrasseur NK, and Fielding RA. Differential activation of 
mTOR signaling by contractile activity in skeletal muscle. Am J Physiol Regul Integr Comp 
Physiol 285: R1086-1090, 2003. 
99. Pearson RB and Thomas G. Regulation of p70s6k/p85s6k and its role in the cell cycle. 
Prog Cell Cycle Res 1: 21-32, 1995. 
100. Pette D and Staron RS. Myosin isoforms, muscle fiber types, and transitions. Microsc Res 
Tech 50: 500-509, 2000. 
101. Pette D and Vrbova G. Neural control of phenotypic expression in mammalian muscle 
fibers. Muscle Nerve 8: 676-689, 1985. 
102. Rees DA and Alcolado JC. Animal models of diabetes mellitus. Diabet Med 22: 359-370, 
2005. 
103. Reiser PJ, Kline WO, and Vaghy PL. Induction of neuronal type nitric oxide synthase in 
skeletal muscle by chronic electrical stimulation in vivo. J Appl Physiol 82: 1250-1255, 
1997. 
104. Rennie MJ, Bohe J, Smith K, Wackerhage H, and Greenhaff P. Branched-chain amino 
acids as fuels and anabolic signals in human muscle. J Nutr 136: 264S-268S, 2006. 
105. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, 
and Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by 
PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009-1013, 2001. 
106. Roy RR, Meadows ID, Baldwin KM, and Edgerton VR. Functional significance of 
compensatory overloaded rat fast muscle. J Appl Physiol 52: 473-478, 1982. 
107. Roy RR, Tri C, Grossman EJ, Talmadge RJ, Grindeland RE, Mukku VR, and Edgerton 
VR. IGF-I, growth hormone, and/or exercise effects on non-weight-bearing soleus of 
hypophysectomized rats. J Appl Physiol 81: 302-311, 1996. 
108. Sakamoto K, Aschenbach WG, Hirshman MF, and Goodyear LJ. Akt signaling in 
skeletal muscle: regulation by exercise and passive stretch. Am J Physiol Endocrinol Metab 
285: E1081-1088, 2003. 
109. Sakamoto K and Goodyear LJ. Invited review: intracellular signaling in contracting 
skeletal muscle. J Appl Physiol 93: 369-383, 2002. 
  98  
 
 
110. Sakamoto K, Hirshman MF, Aschenbach WG, and Goodyear LJ. Contraction 
regulation of Akt in rat skeletal muscle. J Biol Chem 277: 11910-11917, 2002. 
111. Semsarian C, Wu MJ, Ju YK, Marciniec T, Yeoh T, Allen DG, Harvey RP, and Graham 
RM. Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin 
signalling pathway. Nature 400: 576-581, 1999. 
112. Shah OJ, Anthony JC, Kimball SR, and Jefferson LS. 4E-BP1 and S6K1: translational 
integration sites for nutritional and hormonal information in muscle. Am J Physiol 
Endocrinol Metab 279: E715-729, 2000. 
113. Snow MH. Satellite cell response in rat soleus muscle undergoing hypertrophy due to 
surgical ablation of synergists. Anat Rec 227: 437-446, 1990. 
114. Srinivasan K and Ramarao P. Animal models in type 2 diabetes research: an overview. 
Indian J Med Res 125: 451-472, 2007. 
115. Sugiura T, Abe N, Nagano M, Goto K, Sakuma K, Naito H, Yoshioka T, and Powers 
SK. Changes in PKB/Akt and calcineurin signaling during recovery in atrophied soleus 
muscle induced by unloading. Am J Physiol Regul Integr Comp Physiol 288: R1273-1278, 
2005. 
116. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, 
Gualberto A, Wieczorek DF, and Molkentin JD. Prevention of cardiac hypertrophy in 
mice by calcineurin inhibition. Science 281: 1690-1693, 1998. 
117. Swoap SJ, Hunter RB, Stevenson EJ, Felton HM, Kansagra NV, Lang JM, Esser KA, 
and Kandarian SC. The calcineurin-NFAT pathway and muscle fiber-type gene 
expression. Am J Physiol Cell Physiol 279: C915-924, 2000. 
118. Swynghedauw B. Developmental and functional adaptation of contractile proteins in 
cardiac and skeletal muscles. Physiol Rev 66: 710-771, 1986. 
119. Talmadge RJ, Otis JS, Rittler MR, Garcia ND, Spencer SR, Lees SJ, and Naya FJ. 
Calcineurin activation influences muscle phenotype in a muscle-specific fashion. BMC 
Cell Biol 5: 28, 2004. 
120. Talmadge RJ, Roy RR, and Edgerton VR. Myosin heavy chain profile of cat soleus 
following chronic reduced activity or inactivity. Muscle Nerve 19: 980-988, 1996. 
121. Tamaki T and Shiraishi T. Characteristics of compensatory hypertrophied muscle in the 
rat: II. Comparison of histochemical and functional properties. Anat Rec 246: 335-342, 
1996. 
122. Terjung RL, Clarkson P, Eichner ER, Greenhaff PL, Hespel PJ, Israel RG, Kraemer WJ, 
Meyer RA, Spriet LL, Tarnopolsky MA, Wagenmakers AJ, and Williams MH. 
American College of Sports Medicine roundtable. The physiological and health effects of 
oral creatine supplementation. Med Sci Sports Exerc 32: 706-717, 2000. 
123. Tidball JG. Inflammatory processes in muscle injury and repair. Am J Physiol Regul 
Integr Comp Physiol 288: R345-353, 2005. 
124. Timson BF. Evaluation of animal models for the study of exercise-induced muscle 
enlargement. J Appl Physiol 69: 1935-1945, 1990. 
125. Timson BF, Bowlin BK, Dudenhoeffer GA, and George JB. Fiber number, area, and 
composition of mouse soleus muscle following enlargement. J Appl Physiol 58: 619-624, 
1985. 
126. Tokmakidis SP, Zois CE, Volaklis KA, Kotsa K, and Touvra AM. The effects of a 
combined strength and aerobic exercise program on glucose control and insulin action in 
women with type 2 diabetes. Eur J Appl Physiol 92: 437-442, 2004. 
  99  
 
 
127. Tudor-Locke CE, Bell RC, and Meyers AM. Revisiting the role of physical activity and 
exercise in the treatment of type 2 diabetes. Can J Appl Physiol 25: 466-492, 2000. 
128. Turinsky J and Damrau-Abney A. Akt kinases and 2-deoxyglucose uptake in rat 
skeletal muscles in vivo: study with insulin and exercise. Am J Physiol 276: R277-282, 
1999. 
129. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L, Cantoni 
O, Clementi E, Moncada S, Carruba MO, and Nisoli E. TNF-alpha downregulates 
eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin 
Invest 116: 2791-2798, 2006. 
130. Vanhaesebroeck B and Alessi DR. The PI3K-PDK1 connection: more than just a road to 
PKB. Biochem J 346 Pt 3: 561-576, 2000. 
131. Venojarvi M, Puhke R, Hamalainen H, Marniemi J, Rastas M, Rusko H, Nuutila P, 
Hanninen O, and Aunola S. Role of skeletal muscle-fibre type in regulation of glucose 
metabolism in middle-aged subjects with impaired glucose tolerance during a long-term 
exercise and dietary intervention. Diabetes Obes Metab 7: 745-754, 2005. 
132. Vierck J, O'Reilly B, Hossner K, Antonio J, Byrne K, Bucci L, and Dodson M. Satellite 
cell regulation following myotrauma caused by resistance exercise. Cell Biol Int 24: 263-
272, 2000. 
133. Wegner JA, Lund DD, Overton JM, Edwards JG, Oda RP, and Tipton CM. Select 
cardiovascular and metabolic responses of diabetic rats to moderate exercise training. 
Med Sci Sports Exerc 19: 497-503, 1987. 
134. Widrick JJ and Fitts RH. Peak force and maximal shortening velocity of soleus fibers 
after non-weight-bearing and resistance exercise. J Appl Physiol 82: 189-195, 1997. 
135. Willey KA and Singh MA. Battling insulin resistance in elderly obese people with type 
2 diabetes: bring on the heavy weights. Diabetes Care 26: 1580-1588, 2003. 
136. Wong TS and Booth FW. Protein metabolism in rat gastrocnemius muscle after 
stimulated chronic concentric exercise. J Appl Physiol 69: 1709-1717, 1990. 
137. Woscholski R, Waterfield MD, and Parker PJ. Purification and biochemical 
characterization of a mammalian phosphatidylinositol 3,4,5-trisphosphate 5-
phosphatase. J Biol Chem 270: 31001-31007, 1995. 
138. Wu H, Naya FJ, McKinsey TA, Mercer B, Shelton JM, Chin ER, Simard AR, Michel 
RN, Bassel-Duby R, Olson EN, and Williams RS. MEF2 responds to multiple calcium-
regulated signals in the control of skeletal muscle fiber type. Embo J 19: 1963-1973, 2000. 
139. Wu X, Reiter CE, Antonetti DA, Kimball SR, Jefferson LS, and Gardner TW. Insulin 
promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J Biol Chem 
279: 9167-9175, 2004. 
140. Yang H, Alnaqeeb M, Simpson H, and Goldspink G. Changes in muscle fibre type, 
muscle mass and IGF-I gene expression in rabbit skeletal muscle subjected to stretch. J 
Anat 190 (Pt 4): 613-622, 1997. 
141. Yarasheski KE, Lemon PW, and Gilloteaux J. Effect of heavy-resistance exercise 
training on muscle fiber composition in young rats. J Appl Physiol 69: 434-437, 1990. 
142. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, and Shaw J. The metabolic 
syndrome: a global public health problem and a new definition. J Atheroscler Thromb 12: 
295-300, 2005. 
 
 
 
